1
|
Rosso M, Doneva SE, Howells DW, Leenaars CH, Ineichen BV. Summer school for systematic reviews of animal studies: Fostering evidence-based and rigorous animal research. ALTEX 2024; 41:131-134. [PMID: 38204181 DOI: 10.14573/altex.2310251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Indexed: 01/12/2024]
Affiliation(s)
- Marianna Rosso
- Center for Reproducible Science, University of Zurich, Zurich, Switzerland
| | - Simona E Doneva
- Center for Reproducible Science, University of Zurich, Zurich, Switzerland
| | | | | | - Benjamin V Ineichen
- Center for Reproducible Science, University of Zurich, Zurich, Switzerland
- Clinical Neuroscience Center, University of Zurich, Zurich, Switzerland
| |
Collapse
|
2
|
Hirt J, Khanteymoori A, Hohenhaus M, Kopp MA, Howells DW, Schwab JM, Watzlawick R. Inhibition of the Nogo-pathway in experimental spinal cord injury: a meta-analysis of 76 experimental treatments. Sci Rep 2023; 13:22898. [PMID: 38129508 PMCID: PMC10739940 DOI: 10.1038/s41598-023-49260-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 12/06/2023] [Indexed: 12/23/2023] Open
Abstract
Recovery after spinal cord injury (SCI) may be propagated by plasticity-enhancing treatments. The myelin-associated nerve outgrowth inhibitor Nogo-A (Reticulon 4, RTN4) pathway has been shown to restrict neuroaxonal plasticity in experimental SCI models. Early randomized controlled trials are underway to investigate the effect of Nogo-A/Nogo-Receptor (NgR1) pathway blockers. This systematic review and meta-analysis of therapeutic approaches blocking the Nogo-A pathway interrogated the efficacy of functional locomotor recovery after experimental SCI according to a pre-registered study protocol. A total of 51 manuscripts reporting 76 experiments in 1572 animals were identified for meta-analysis. Overall, a neurobehavioral improvement by 18.9% (95% CI 14.5-23.2) was observed. Subgroup analysis (40 experiments, N = 890) revealed SCI-modelling factors associated with outcome variability. Lack of reported randomization and smaller group sizes were associated with larger effect sizes. Delayed treatment start was associated with lower effect sizes. Trim and Fill assessment as well as Egger regression suggested the presence of publication bias. Factoring in theoretically missing studies resulted in a reduced effect size [8.8% (95% CI 2.6-14.9)]. The available data indicates that inhibition of the Nogo-A/NgR1pathway alters functional recovery after SCI in animal studies although substantial differences appear for the applied injury mechanisms and other study details. Mirroring other SCI interventions assessed earlier we identify similar factors associated with outcome heterogeneity.
Collapse
Affiliation(s)
- Julian Hirt
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Alireza Khanteymoori
- Department of Neurosurgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany
| | - Marc Hohenhaus
- Department of Neurosurgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany
| | - Marcel A Kopp
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - David W Howells
- Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia
| | - Jan M Schwab
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology, Spinal Cord Injury Division (Paraplegiology), The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA
- Belford Center for Spinal Cord Injury, Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA
| | - Ralf Watzlawick
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Neurosurgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany.
| |
Collapse
|
3
|
Brown LS, King NE, Courtney JM, Gasperini RJ, Foa L, Howells DW, Sutherland BA. Brain pericytes in culture display diverse morphological and functional phenotypes. Cell Biol Toxicol 2023; 39:2999-3014. [PMID: 37322257 PMCID: PMC10693527 DOI: 10.1007/s10565-023-09814-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 05/23/2023] [Indexed: 06/17/2023]
Abstract
Pericytes play several important functions in the neurovascular unit including contractile control of capillaries, maintenance of the BBB, regulation of angiogenesis, and neuroinflammation. There exists a continuum of pericyte subtypes along the vascular tree which exhibit both morphological and transcriptomic differences. While different functions have been associated with the pericyte subtypes in vivo, numerous recent publications have used a primary human brain vascular pericytes (HBVP) cell line where this pericyte heterogeneity has not been considered. Here, we used primary HBVP cultures, high-definition imaging, cell motility tracking, and immunocytochemistry to characterise morphology, protein expression, and contractile behaviour to determine whether heterogeneity of pericytes also exists in cultures. We identified five distinct morphological subtypes that were defined using both qualitative criteria and quantitative shape analysis. The proportion of each subtype present within the culture changed as passage number increased, but pericytes did not change morphological subtype over short time periods. The rate and extent of cellular and membrane motility differed across the subtypes. Immunocytochemistry revealed differential expression of alpha-smooth muscle actin (αSMA) across subtypes. αSMA is essential for cell contractility, and consequently, only subtypes with high αSMA expression contracted in response to physiological vasoconstrictors endothelin-1 (ET1) and noradrenaline (NA). We conclude that there are distinct morphological subtypes in HBVP culture, which display different behaviours. This has significance for the use of HBVP when modelling pericyte physiology in vitro where relevance to in vivo pericyte subtypes along the vascular tree must be considered.
Collapse
Affiliation(s)
- Lachlan S Brown
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Level 4 Medical Sciences Precinct, 17 Liverpool St, Hobart, TAS, 7000, Australia
| | - Natalie E King
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Level 4 Medical Sciences Precinct, 17 Liverpool St, Hobart, TAS, 7000, Australia
| | - Jo-Maree Courtney
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Level 4 Medical Sciences Precinct, 17 Liverpool St, Hobart, TAS, 7000, Australia
| | - Robert J Gasperini
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Level 4 Medical Sciences Precinct, 17 Liverpool St, Hobart, TAS, 7000, Australia
| | - Lisa Foa
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Level 4 Medical Sciences Precinct, 17 Liverpool St, Hobart, TAS, 7000, Australia
- School of Psychological Sciences, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
| | - David W Howells
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Level 4 Medical Sciences Precinct, 17 Liverpool St, Hobart, TAS, 7000, Australia
| | - Brad A Sutherland
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Level 4 Medical Sciences Precinct, 17 Liverpool St, Hobart, TAS, 7000, Australia.
| |
Collapse
|
4
|
Morris GP, Foster CG, Courtney J, Collins JM, Cashion JM, Brown LS, Howells DW, DeLuca GC, Canty AJ, King AE, Ziebell JM, Sutherland BA. Microglia directly associate with pericytes in the central nervous system. Glia 2023; 71:1847-1869. [PMID: 36994950 PMCID: PMC10952742 DOI: 10.1002/glia.24371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 03/15/2023] [Accepted: 03/20/2023] [Indexed: 03/31/2023]
Abstract
Cerebral blood flow (CBF) is important for the maintenance of brain function and its dysregulation has been implicated in Alzheimer's disease (AD). Microglia associations with capillaries suggest they may play a role in the regulation of CBF or the blood-brain-barrier (BBB). We explored the relationship between microglia and pericytes, a vessel-resident cell type that has a major role in the control of CBF and maintenance of the BBB, discovering a spatially distinct subset of microglia that closely associate with pericytes. We termed these pericyte-associated microglia (PEM). PEM are present throughout the brain and spinal cord in NG2DsRed × CX3 CR1+/GFP mice, and in the human frontal cortex. Using in vivo two-photon microscopy, we found microglia residing adjacent to pericytes at all levels of the capillary tree and found they can maintain their position for at least 28 days. PEM can associate with pericytes lacking astroglial endfeet coverage and capillary vessel width is increased beneath pericytes with or without an associated PEM, but capillary width decreases if a pericyte loses a PEM. Deletion of the microglia fractalkine receptor (CX3 CR1) did not disrupt the association between pericytes and PEM. Finally, we found the proportion of microglia that are PEM declines in the superior frontal gyrus in AD. In summary, we identify microglia that specifically associate with pericytes and find these are reduced in number in AD, which may be a novel mechanism contributing to vascular dysfunction in neurodegenerative diseases.
Collapse
Affiliation(s)
- Gary P. Morris
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Catherine G. Foster
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Jo‐Maree Courtney
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Jessica M. Collins
- Wicking Dementia Research and Education Centre, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Jake M. Cashion
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Lachlan S. Brown
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - David W. Howells
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Gabriele C. DeLuca
- Nuffield Department of Clinical NeurosciencesUniversity of OxfordOxfordUK
| | - Alison J. Canty
- Wicking Dementia Research and Education Centre, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
- Global Brain Health InstituteTrinity CollegeDublinIreland
| | - Anna E. King
- Wicking Dementia Research and Education Centre, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Jenna M. Ziebell
- Wicking Dementia Research and Education Centre, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Brad A. Sutherland
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| |
Collapse
|
5
|
Morris GP, Gowing EK, Courtney J, Coombe HE, King NE, Rewell SSJ, Howells DW, Clarkson AN, Sutherland BA. Vascular perfusion differs in two distinct PDGFRβ-positive zones within the ischemic core of male mice 2 weeks following photothrombotic stroke. J Neurosci Res 2023; 101:278-292. [PMID: 36412274 PMCID: PMC10952185 DOI: 10.1002/jnr.25146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 10/07/2022] [Accepted: 11/06/2022] [Indexed: 11/23/2022]
Abstract
Stroke therapy has largely focused on preventing damage and encouraging repair outside the ischemic core, as the core is considered irreparable. Recently, several studies have suggested endogenous responses within the core are important for limiting the spread of damage and enhancing recovery, but the role of blood flow and capillary pericytes in this process is unknown. Using the Rose Bengal photothrombotic model of stroke, we illustrate blood vessels are present in the ischemic core and peri-lesional regions 2 weeks post stroke in male mice. A FITC-albumin gel cast of the vasculature revealed perfusion of these vessels, suggesting cerebral blood flow (CBF) may be partially present, without vascular leakage. The length of these vessels is significantly reduced compared to uninjured regions, but the average width is greater, suggesting they are either larger vessels that survived the initial injury, smaller vessels that have expanded in size (i.e., arteriogenesis), or that neovascularization begins with larger vessels. Concurrently, we observed an increase in platelet-derived growth factor receptor beta (PDGFRβ, a marker of pericytes) expression within the ischemic core in two distinct patterns, one which resembles pericyte-derived fibrotic scarring at the edge of the core, and one which is vessel associated and may represent blood vessel recovery. We find little evidence for dividing cells on these intralesional blood vessels 2 weeks post stroke. Our study provides evidence flow is present in PDGFRβ-positive vessels in the ischemic core 2 weeks post stroke. We hypothesize intralesional CBF is important for limiting injury and for encouraging endogenous repair following cerebral ischemia.
Collapse
Affiliation(s)
- Gary P. Morris
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Emma K. Gowing
- Department of Anatomy, Brain Health Research Centre and Brain Research New ZealandUniversity of OtagoDunedinNew Zealand
| | - Jo‐Maree Courtney
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Hannah E. Coombe
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Natalie E. King
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Sarah S. J. Rewell
- Florey Institute of Neuroscience and Mental HealthMelbourne Brain Centre, Austin CampusHeidelbergVictoriaAustralia
| | - David W. Howells
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| | - Andrew N. Clarkson
- Department of Anatomy, Brain Health Research Centre and Brain Research New ZealandUniversity of OtagoDunedinNew Zealand
| | - Brad A. Sutherland
- Tasmanian School of Medicine, College of Health and MedicineUniversity of TasmaniaHobartTasmaniaAustralia
| |
Collapse
|
6
|
Aiyede M, Lim XY, Russell AAM, Patel RP, Gueven N, Howells DW, Bye N. A Systematic Review and Meta-Analysis on the Therapeutic Efficacy of Heparin and Low Molecular Weight Heparins in Animal Studies of Traumatic Brain Injury. J Neurotrauma 2023; 40:4-21. [PMID: 35880422 DOI: 10.1089/neu.2022.0020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
The identification of effective pharmacotherapies for traumatic brain injury (TBI) remains a major challenge. Treatment with heparin and its derivatives is associated with neuroprotective effects after experimental TBI; however, the optimal dosage and method of administration, modes of action, and effects on hemorrhage remain unclear. Therefore, this review aimed to systematically evaluate, analyze, and summarize the available literature on the use of heparin and low molecular weight heparins (LMWHs) as treatment options for experimental TBI. We searched two online databases (PubMed and ISI Web of Science) to identify relevant studies. Data pertaining to TBI paradigm, animal subjects, drug administration, and all pathological and behavior outcomes were extracted. Eleven studies met our pre-specified inclusion criteria, and for outcomes with sufficient numbers, data from seven publications were analyzed in a weighted mean difference meta-analysis using a random-effects model. Study quality and risk of bias were also determined. Meta-analysis revealed that heparin and its derivatives decreased brain edema, leukocyte rolling, and vascular permeability, and improved neurological function. Further, treatment did not aggravate hemorrhage. These findings must be interpreted with caution, however, because they were determined from a limited number of studies with substantial heterogeneity. Also, overall study quality was low based on absences of data reporting, and potential publication bias was identified. Importantly, we found that there are insufficient data to evaluate the variables we had hoped to investigate. The beneficial effects of heparin and LMWHs, however, suggest that further pre-clinical studies are warranted.
Collapse
Affiliation(s)
- Mimieveshiofuo Aiyede
- School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia
| | - Xin Yi Lim
- Herbal Medicine Research Centre, Institute for Medical Research, Ministry of Health, Kuala Lumpur, Malaysia
| | - Ash A M Russell
- School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Rahul P Patel
- School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia
| | - Nuri Gueven
- School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia
| | - David W Howells
- School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Nicole Bye
- School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
7
|
Courtney JM, Morris GP, Cleary EM, Howells DW, Sutherland BA. Automated Quantification of Multiple Cell Types in Fluorescently Labeled Whole Mouse Brain Sections Using QuPath. Bio Protoc 2022; 12:e4459. [PMID: 35937935 PMCID: PMC9303822 DOI: 10.21769/bioprotoc.4459] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 05/27/2022] [Accepted: 05/31/2022] [Indexed: 12/29/2022] Open
Abstract
The quantification of labeled cells in tissue sections is crucial to the advancement of biological knowledge. Traditionally, this was a tedious process, requiring hours of careful manual counting in small portions of a larger tissue section. To overcome this, many automated methods for cell analysis have been developed. Recent advances in whole slide scanning technologies have provided the means to image cells in entire tissue sections. However, common automated analysis tools do not have the capacity to deal with the large image files produced. Herein, we present a protocol for the quantification of two fluorescently labeled cell populations, namely pericytes and microglia, in whole brain tissue sections. This protocol uses custom-made scripts within the open source software QuPath to provide a framework for the careful optimization and validation of automated cell detection parameters. Images obtained from a whole-slide scanner are first loaded into a QuPath project. Manual counts are performed on small sample regions to optimize cell detection parameters prior to automated quantification of cells across entire brain regions. Even though we have quantified pericytes and microglia, any fluorescently labeled cell with clear labeling in and around the nucleus can be analyzed using these methods. This protocol provides a user-friendly and cost-effective framework for the automated analysis of whole tissue sections.
Collapse
Affiliation(s)
- Jo-Maree Courtney
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Gary P. Morris
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Elise M. Cleary
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - David W. Howells
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Brad A. Sutherland
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
,
*For correspondence:
| |
Collapse
|
8
|
McCafferty C, Lee L, Cai T, Praporski S, Stolper J, Karlaftis V, Attard C, Myint D, Carey LM, Howells DW, Donnan GA, Davis S, Ma H, Crewther S, Nguyen VA, Van Den Helm S, Letunica N, Swaney E, Elliott D, Subbarao K, Ignjatovic V, Monagle P. Fibrin clot characteristics and anticoagulant response in a SARS‐CoV‐2‐infected endothelial model. eJHaem 2022; 3:326-334. [PMID: 35602246 PMCID: PMC9110985 DOI: 10.1002/jha2.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 02/16/2022] [Accepted: 02/18/2022] [Indexed: 11/17/2022]
Abstract
Coronavirus disease 2019 (COVID‐19) patients have increased thrombosis risk. With increasing age, there is an increase in COVID‐19 severity. Additionally, adults with a history of vasculopathy have the highest thrombotic risk in COVID‐19. The mechanisms of these clinical differences in risk remain unclear. Human umbilical vein endothelial cells (HUVECs) were infected with SARS‐CoV‐2, influenza A/Singapore/6/86 (H1N1) or mock‐infected prior to incubation with plasma from healthy children, healthy adults or vasculopathic adults. Fibrin on surface of cells was observed using scanning electron microscopy, and fibrin characteristics were quantified. This experiment was repeated in the presence of bivalirudin, defibrotide, low‐molecular‐weight‐heparin (LMWH) and unfractionated heparin (UFH). Fibrin formed on SARS‐CoV‐2 infected HUVECs was densely packed and contained more fibrin compared to mock‐infected cells. Fibrin generated from child plasma was the thicker than fibrin generated in vasculopathic adult plasma (p = 0.0165). Clot formation was inhibited by LMWH (0.5 U/ml) and UFH (0.1–0.7 U/ml). We show that in the context of the SARS‐CoV‐2 infection on an endothelial culture, plasma from vasculopathic adults produces fibrin clots with thinner fibrin, indicating that the plasma coagulation system may play a role in determining the thrombotic outcome of SARS‐CoV‐2 infection. Heparinoid anticoagulants were most effective at preventing clot formation.
Collapse
Affiliation(s)
- Conor McCafferty
- Department of Paediatrics The University of Melbourne Melbourne Victoria Australia
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Leo Lee
- Department of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity The University of Melbourne Melbourne Victoria Australia
| | - Tengyi Cai
- Department of Paediatrics The University of Melbourne Melbourne Victoria Australia
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Slavica Praporski
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Julian Stolper
- Heart Regeneration Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Vasiliki Karlaftis
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Chantal Attard
- Department of Paediatrics The University of Melbourne Melbourne Victoria Australia
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - David Myint
- TA Scientific Pty. Ltd. Taren Point Sydney New South Wales Australia
| | - Leeanne M. Carey
- Department of Occupational Therapy Social Work and Social Policy La Trobe University Melbourne Victoria Australia
- Neurorehabilitation and Recovery Florey Institute of Neuroscience and Mental Health University of Melbourne Melbourne Victoria Australia
| | - David W. Howells
- Tasmanian School of Medicine University of Tasmania Hobart Tasmania Australia
| | - Geoffrey A. Donnan
- Melbourne Brain Centre Royal Melbourne Hospital and University of Melbourne Melbourne Victoria Australia
| | - Stephen Davis
- Melbourne Brain Centre Royal Melbourne Hospital and University of Melbourne Melbourne Victoria Australia
| | - Henry Ma
- Department of Neurology and Stroke Monash Health Hospital Melbourne Victoria Australia
| | - Sheila Crewther
- Department of Psychology and Counselling La Trobe University Melbourne Victoria Australia
| | - Vinh A. Nguyen
- Department of Psychology and Counselling La Trobe University Melbourne Victoria Australia
| | - Suelyn Van Den Helm
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Natasha Letunica
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Ella Swaney
- Department of Paediatrics The University of Melbourne Melbourne Victoria Australia
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - David Elliott
- Heart Regeneration Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Kanta Subbarao
- Department of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity The University of Melbourne Melbourne Victoria Australia
- WHO Collaborating Centre for Reference and Research on Influenza The Peter Doherty Institute for Infection and Immunity Melbourne Victoria Australia
| | - Vera Ignjatovic
- Department of Paediatrics The University of Melbourne Melbourne Victoria Australia
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
| | - Paul Monagle
- Department of Paediatrics The University of Melbourne Melbourne Victoria Australia
- Haematology Murdoch Children's Research Institute Melbourne Victoria Australia
- Department of Clinical Haematology The Royal Children's Hospital Melbourne Victoria Australia
- Kids Cancer Centre Sydney Children's Hospital Randwick New South Wales Australia
| |
Collapse
|
9
|
Russell AAM, Sutherland BA, Landowski LM, Macleod M, Howells DW. What has preclinical systematic review ever done for us? BMJ Open Science 2022; 6:e100219. [PMID: 35360370 PMCID: PMC8921935 DOI: 10.1136/bmjos-2021-100219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022] Open
Abstract
Systematic review and meta-analysis are a gift to the modern researcher, delivering a crystallised understanding of the existing research data in any given space. This can include whether candidate drugs are likely to work or not and which are better than others, whether our models of disease have predictive value and how this might be improved and also how these all interact with disease pathophysiology.Grappling with the literature needed for such analyses is becoming increasingly difficult as the number of publications grows. However, narrowing the focus of a review to reduce workload runs the risk of diminishing the generalisability of conclusions drawn from such increasingly specific analyses.Moreover, at the same time as we gain greater insight into our topic, we also discover more about the flaws that undermine much scientific research. Systematic review and meta-analysis have also shown that the quality of much preclinical research is inadequate. Systematic review has helped reveal the extent of selection bias, performance bias, detection bias, attrition bias and low statistical power, raising questions about the validity of many preclinical research studies. This is perhaps the greatest virtue of systematic review and meta-analysis, the knowledge generated ultimately helps shed light on the limitations of existing research practice, and in doing so, helps bring reform and rigour to research across the sciences.In this commentary, we explore the lessons that we have identified through the lens of preclinical systematic review and meta-analysis.
Collapse
Affiliation(s)
- Ash Allanna Mark Russell
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Brad A Sutherland
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Lila M Landowski
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
- School of Health Sciences, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Malcolm Macleod
- Centre for Clinical Brain Sciences, Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK
| | - David W Howells
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
10
|
Zwetsloot PP, Antonic-Baker A, Gremmels H, Wever K, Sena C, Jansen Of Lorkeers S, Chamuleau S, Sluijter J, Howells DW. Combined meta-analysis of preclinical cell therapy studies shows overlapping effect modifiers for multiple diseases. BMJ Open Sci 2022; 5:e100061. [PMID: 35047695 PMCID: PMC8647619 DOI: 10.1136/bmjos-2020-100061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 02/08/2021] [Accepted: 03/15/2021] [Indexed: 12/30/2022] Open
Abstract
Introduction Cell therapy has been studied in many different research domains. Cellular replacement of damaged solid tissues is at an early stage of development, with much still to be understood. Systematic reviews and meta-analyses are widely used to aggregate data and find important patterns of results within research domains. We set out to find common biological denominators affecting efficacy in preclinical cell therapy studies for renal, neurological and cardiac disease. Methods We used datasets of five previously published meta-analyses investigating cell therapy in preclinical models of chronic kidney disease, spinal cord injury, stroke and ischaemic heart disease. We transformed primary outcomes to ratios of means to permit direct comparison across disease areas. Prespecified variables of interest were species, immunosuppression, cell type, cell origin, dose, delivery and timing of the cell therapy. Results The five datasets from 506 publications yielded data from 13 638 animals. Animal size affects therapeutic efficacy in an inverse manner. Cell type influenced efficacy in multiple datasets differently, with no clear trend for specific cell types being superior. Immunosuppression showed a negative effect in spinal cord injury and a positive effect in cardiac ischaemic models. There was a dose–dependent relationship across the different models. Pretreatment seems to be superior compared with administration after the onset of disease. Conclusions Preclinical cell therapy studies are affected by multiple variables, including species, immunosuppression, dose and treatment timing. These data are important when designing preclinical studies before commencing clinical trials.
Collapse
Affiliation(s)
| | - Ana Antonic-Baker
- Neuroscience, Monash University, Melbourne, Victoria, Australia.,Department of Neuroscience, The Alfred Central Clinical School Monash University, Melbourne, Victoria, Australia
| | | | - Kimberley Wever
- Systematic Review Centre for Laboratory Animal Experimentation, Radboud Universiteit, Nijmegen, Gelderland, The Netherlands
| | - Chris Sena
- Department of Clinical Neurosciences, Edinburgh Royal Infirmary, Edinburgh, UK
| | | | - Steven Chamuleau
- Cardiology, UMC Utrecht, Utrecht, The Netherlands.,Cardiology, Amsterdam UMC, Amsterdam, Noord-Holland, The Netherlands
| | - Joost Sluijter
- Experimental Cardiology, UMC Utrecht, Utrecht, The Netherlands
| | - David W Howells
- School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
11
|
Nguyen VA, Crewther SG, Howells DW, Wijeratne T, Ma H, Hankey GJ, Davis S, Donnan GA, Carey LM. Acute Routine Leukocyte and Neutrophil Counts Are Predictive of Poststroke Recovery at 3 and 12 Months Poststroke: An Exploratory Study. Neurorehabil Neural Repair 2021; 34:844-855. [PMID: 32940147 DOI: 10.1177/1545968320948607] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Background and Aims. White blood cell (WBC) and neutrophil counts (NC) are common markers of inflammation and neurological stroke damage and could be expected to predict poststroke outcomes. Objective. The aim of this study was to explore the prognostic value of early poststroke WBC and NC to predict cognition, mood, and disability outcomes at 3 and 12 months poststroke. Methods. Routine clinical analyses WBC and NC were collected at 3 time points in the first 4 days of hospitalization from 156 acute stroke patients. Correlations using hierarchical or ordinal regressions were explored between acute WBC and NC and functional recovery, depression, and cognition at 3 and 12 months poststroke, after covarying for age and baseline stroke severity. Results. We found significant increases in NC between <12 hours and 24 to 48 hours time points (P = .05). Hierarchical regressions, covaried for age and baseline stroke severity, found that 24 to 48 hours WBC (P = .05) and NC (P = .04) significantly predicted 3-month cognition scores. Similarly, 24 to 48 hours WBC (P = .05) and NC (P = .02) predicted cognition scores at 12 months. Increases in WBC and NC were predictive of increased cognition scores at both 3 and 12 months (positive recovery) though there were no significant associations between WBC and NC and disability or depression scores. Conclusions. Routine acute stroke clinical laboratory tests such as WBC and NC taken between 24 and 48 hours poststroke are predictive of cognition poststroke. It is interpreted that higher rapid immunological activation in the acute phase is an indicator for the trajectory of positive stroke recovery.
Collapse
Affiliation(s)
- Vinh A Nguyen
- La Trobe University, College of Science, Health and Engineering, Bundoora, Victoria, Australia.,The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia
| | - Sheila G Crewther
- La Trobe University, College of Science, Health and Engineering, Bundoora, Victoria, Australia
| | | | - Tissa Wijeratne
- Melbourne Medical School, Western Health, Sunshine Hospital, St Albans, Victoria, Australia
| | - Henry Ma
- Department of Medcine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
| | - Graeme J Hankey
- University of Western Australia, Perth, Western Australia, Australia
| | - Stephen Davis
- Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Parkville, Victoria, Australia
| | - Geoffrey A Donnan
- Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Parkville, Victoria, Australia
| | - Leeanne M Carey
- La Trobe University, College of Science, Health and Engineering, Bundoora, Victoria, Australia.,The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia
| |
Collapse
|
12
|
Lo EH, Albers GW, Dichgans M, Donnan G, Esposito E, Foster R, Howells DW, Huang YG, Ji X, Klerman EB, Lee S, Li W, Liebeskind DS, Lizasoain I, Mandeville ET, Moro MA, Ning M, Ray D, Sakadžić S, Saver JL, Scheer FAJL, Selim M, Tiedt S, Zhang F, Buchan AM. Circadian Biology and Stroke. Stroke 2021; 52:2180-2190. [PMID: 33940951 DOI: 10.1161/strokeaha.120.031742] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Circadian biology modulates almost all aspects of mammalian physiology, disease, and response to therapies. Emerging data suggest that circadian biology may significantly affect the mechanisms of susceptibility, injury, recovery, and the response to therapy in stroke. In this review/perspective, we survey the accumulating literature and attempt to connect molecular, cellular, and physiological pathways in circadian biology to clinical consequences in stroke. Accounting for the complex and multifactorial effects of circadian rhythm may improve translational opportunities for stroke diagnostics and therapeutics.
Collapse
Affiliation(s)
- Eng H Lo
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Radiology (E.H.L., E.E., W.L., E.T.M., S.S., F.Z.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Gregory W Albers
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Neurology, Stanford Stroke Center, Stanford University, Palo Alto (G.W.A., S.L.)
| | - Martin Dichgans
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,German Center for Neurodegenerative Diseases (DZNE, Munich) and Munich Cluster for Systems Neurology (SyNergy), Germany (M.D.).,Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Germany (M.D., S.T.)
| | - Geoffrey Donnan
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Australia (G.D.)
| | - Elga Esposito
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Radiology (E.H.L., E.E., W.L., E.T.M., S.S., F.Z.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Russell Foster
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences (R.F.), University of Oxford, United Kingdom
| | - David W Howells
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Tasmanian School of Medicine, University of Tasmania, Australia (D.W.H.)
| | - Yi-Ge Huang
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Stroke Medicine (Y.H., A.M.B.), University of Oxford, United Kingdom
| | - Xunming Ji
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Beijing Institute for Brain Disorders, China (X.J.)
| | - Elizabeth B Klerman
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Neurology (E.B.K., M.N.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Sarah Lee
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Neurology, Stanford Stroke Center, Stanford University, Palo Alto (G.W.A., S.L.)
| | - Wenlu Li
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Radiology (E.H.L., E.E., W.L., E.T.M., S.S., F.Z.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - David S Liebeskind
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Neurology, Geffen School of Medicine, University of California Los Angeles (J.L.S., D.S.L.)
| | - Ignacio Lizasoain
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Pharmacology and Toxicology, Complutense Medical School, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain (I.L.)
| | - Emiri T Mandeville
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Radiology (E.H.L., E.E., W.L., E.T.M., S.S., F.Z.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Maria A Moro
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain (M.A.M.)
| | - MingMing Ning
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Neurology (E.B.K., M.N.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - David Ray
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, and Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, United Kingdom (D.R.)
| | - Sava Sakadžić
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Radiology (E.H.L., E.E., W.L., E.T.M., S.S., F.Z.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Jeffrey L Saver
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Neurology, Geffen School of Medicine, University of California Los Angeles (J.L.S., D.S.L.)
| | - Frank A J L Scheer
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Medicine and Neurology, Brigham & Women's Hospital (F.A.J.L.S.), Harvard Medical School, Boston
| | - Magdy Selim
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Neurology, Beth Israel Deaconess Medical Center (M.S.), Harvard Medical School, Boston
| | - Steffen Tiedt
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Germany (M.D., S.T.)
| | - Fang Zhang
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Departments of Radiology (E.H.L., E.E., W.L., E.T.M., S.S., F.Z.), Massachusetts General Hospital, Harvard Medical School, Boston
| | - Alastair M Buchan
- CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.,Department of Stroke Medicine (Y.H., A.M.B.), University of Oxford, United Kingdom
| |
Collapse
|
13
|
Abstract
Background: Distinguishing between stroke subtypes and knowing the time of stroke onset are critical in clinical practice. Thrombolysis and thrombectomy are very effective treatments in selected patients with acute ischemic stroke. Neuroimaging helps decide who should be treated and how they should be treated but is expensive, not always available and can have contraindications. These limitations contribute to the under use of these reperfusion therapies. Aim: An alternative approach in acute stroke diagnosis is to identify blood biomarkers which reflect the body's response to the damage caused by the different types of stroke. Specific blood biomarkers capable of differentiating ischemic from hemorrhagic stroke and mimics, identifying large vessel occlusion and capable of predicting stroke onset time would expedite diagnosis and increase eligibility for reperfusion therapies. Summary of Review: To date, measurements of candidate biomarkers have usually occurred beyond the time window for thrombolysis. Nevertheless, some candidate markers of brain tissue damage, particularly the highly abundant glial structural proteins like GFAP and S100β and the matrix protein MMP-9 offer promising results. Grouping of biomarkers in panels can offer additional specificity and sensitivity for ischemic stroke diagnosis. Unbiased “omics” approaches have great potential for biomarker identification because of greater gene, protein, and metabolite coverage but seem unlikely to be the detection methodology of choice because of their inherent cost. Conclusion: To date, despite the evolution of the techniques used in their evaluation, no individual candidate or multimarker panel has proven to have adequate performance for use in an acute clinical setting where decisions about an individual patient are being made. Timing of biomarker measurement, particularly early when decision making is most important, requires urgent and systematic study.
Collapse
Affiliation(s)
- Marie Dagonnier
- Stroke Division, Melbourne Brain Centre, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia.,Department of Neurology, Ambroise Paré Hospital, Mons, Belgium
| | - Geoffrey A Donnan
- Stroke Division, Melbourne Brain Centre, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia.,Melbourne Brain Centre at the Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia
| | - Stephen M Davis
- Melbourne Brain Centre at the Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia
| | - Helen M Dewey
- Stroke Division, Melbourne Brain Centre, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia.,Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia
| | - David W Howells
- Stroke Division, Melbourne Brain Centre, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia.,Faculty of Health, School of Medicine, University of Tasmania, Hobart, TAS, Australia
| |
Collapse
|
14
|
Foster CG, Landowski LM, Sutherland BA, Howells DW. Differences in fatigue-like behavior in the lipopolysaccharide and poly I:C inflammatory animal models. Physiol Behav 2021; 232:113347. [PMID: 33529685 DOI: 10.1016/j.physbeh.2021.113347] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 01/18/2021] [Accepted: 01/29/2021] [Indexed: 11/30/2022]
Abstract
Central fatigue is a condition associated with impairment of the central nervous system often leading to the manifestation of a range of debilitating symptoms. Fatigue can be a consequence of systemic inflammation following an infection. Administration of lipopolysaccharide (LPS) and polyriboinosinic:polyribocytidlic (poly I:C) to animals can induce systemic inflammation by mimicking a bacterial or viral infection respectively and therefore have been used as models of fatigue. We evaluated a range of phenotypic behaviors exhibited in the LPS and poly I:C animal models to assess whether they adequately replicate fatigue symptomology in humans. In addition to standard observation- and intervention-based behavioral assessments, we used powerful in-cage monitoring technology to quantify rodent behavior without external interference. LPS and poly I:C treated Sprague Dawley rats displayed 'sickness behaviors' of elevated temperature, weight loss and reduced activity in the open field test and with in-cage monitoring within 24 h post-treatment, but only LPS-treated rats displayed these behaviors beyond these acute timepoints. Once sickness behavior diminished, LPS-treated rats exhibited an increase in reward-seeking and motivation behaviors. Overall, these results suggest that the LPS animal model produces an extensive and sustained fatigue-like phenotype, whereas the poly I:C model only produced acute effects. Our results suggest that the LPS animal model is a more suitable candidate for further studies on central fatigue-like behavior.
Collapse
Affiliation(s)
- Catherine G Foster
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia
| | - Lila M Landowski
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia
| | - Brad A Sutherland
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia
| | - David W Howells
- Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia.
| |
Collapse
|
15
|
Landowski LM, Livesey KL, Bibari O, Russell AM, Taylor MR, Ho CC, Howells DW, Fuller RO. Optimisation of Iron Oxide Nanoparticles for Agglomeration and Blockage in Aqueous Flow Systems. Aust J Chem 2021. [DOI: 10.1071/ch21061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
16
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Physiol 2020; 598:3793-3801. [PMID: 32666574 PMCID: PMC7610696 DOI: 10.1113/jp280389] [Citation(s) in RCA: 159] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 06/23/2020] [Indexed: 12/14/2022] Open
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the 'ARRIVE Essential 10,' which constitutes the minimum requirement, and the 'Recommended Set,' which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Collapse
Affiliation(s)
| | - Viki Hurst
- Science Manager – Experimental Design and Reporting, NC3Rs, London, United Kingdom
| | - Amrita Ahluwalia
- Professor of Vascular Pharmacology, Co-Director, The William Harvey Research Institute, London, United Kingdom
- Director of the Barts Cardiovascular CTU, Queen Mary University of London, London, United Kingdom
| | - Sabina Alam
- Director of Publishing Ethics and Integrity, Taylor & Francis Group, London, United Kingdom
| | - Marc T. Avey
- Lead Health Scientist, Health Science Practice, ICF, Durham, North Carolina, United States of America
| | - Monya Baker
- Senior Editor, Opinion, Nature, San Francisco, California, United States of America
| | - William J. Browne
- Professor of Statistics, School of Education, University of Bristol, Bristol, United Kingdom
| | - Alejandra Clark
- Senior Editor, Team Manager – Life Sciences, PLOS ONE, Cambridge, United Kingdom
| | - Innes C. Cuthill
- Professor of Behavioural Ecology, School of Biological Sciences, University of Bristol, Bristol, United Kingdom
| | - Ulrich Dirnagl
- Director, QUEST Center for Transforming Biomedical Research, Berlin Institute of Health & Department of Experimental Neurology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- Reader in Platelet Pharmacology, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Paul Garner
- Professor, and Director of the Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicin Liverpool, United Kingdom
| | - Stephen T. Holgate
- MRC Clinical Professor, Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
| | - David W. Howells
- Professor of Neuroscience and Brain Plasticity, Tasmanian School of Medicine, University of Tasmania, Hobart, Australia
| | - Natasha A. Karp
- Principal Scientist– Statistician & UK Team Lead, Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, Unite Kingdom
| | | | - Katie Lidster
- Programme Manager – Animal Welfare, NC3Rs, London, United Kingdom
| | | | - Malcolm Macleod
- Professor of Neurology and Translational Neuroscience, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Academic Lead for Research Improvement and Research Integrity, University of Edinburgh, Edinburgh, United Kingdom
| | - Esther J. Pearl
- Programme Manager – Experimental Design, NC3Rs, London, United Kingdom
| | - Ole H. Petersen
- Director of the Academia Europaea Knowledge Hub, Cardiff University, Cardiff, United Kingdom
| | - Frances Rawle
- Director of Policy, Ethics and Governance, Medical Research Council, London, United Kingdom
| | - Penny Reynolds
- Biostatistician, Statistics in Anesthesiology Research (STAR) Core & Research Assistant Professor, Department of Anesthesiology College of Medicin University of Florida, Gainesville, Florida, United States of America
| | - Kieron Rooney
- Associate Professor, Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Emily S. Sena
- Stroke Association Kirby Laing Foundation Senior Non-Clinical Lecturer, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburg United Kingdom
| | - Shai D. Silberberg
- Director of Research Quality, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America
| | - Thomas Steckler
- Associate Director, BRQC Animal Welfare Strategy Lead, Janssen Pharmaceutica NV, Beerse, Belgium
| | - Hanno Würbel
- Professor for Animal Welfare, Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
17
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. J Cereb Blood Flow Metab 2020; 40:1769-1777. [PMID: 32663096 PMCID: PMC7430098 DOI: 10.1177/0271678x20943823] [Citation(s) in RCA: 499] [Impact Index Per Article: 124.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 06/30/2020] [Indexed: 01/04/2023]
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the "ARRIVE Essential 10," which constitutes the minimum requirement, and the "Recommended Set," which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Collapse
Affiliation(s)
| | - Viki Hurst
- Science Manager – Experimental Design and Reporting, NC3Rs, London, United Kingdom
| | - Amrita Ahluwalia
- Professor of Vascular Pharmacology, Co-Director, The William Harvey Research Institute, London, United Kingdom
- Director of the Barts Cardiovascular CTU, Queen Mary University of London, London, United Kingdom
| | - Sabina Alam
- Director of Publishing Ethics and Integrity, Taylor & Francis Group, London, United Kingdom
| | - Marc T. Avey
- Lead Health Scientist, Health Science Practice, ICF, Durham, North Carolina, United States of America
| | - Monya Baker
- Senior Editor, Opinion, Nature, San Francisco, California, United States of America
| | - William J. Browne
- Professor of Statistics, School of Education, University of Bristol, Bristol, United Kingdom
| | - Alejandra Clark
- Senior Editor, Team Manager – Life Sciences, PLOS ONE, Cambridge, United Kingdom
| | - Innes C. Cuthill
- Professor of Behavioural Ecology, School of Biological Sciences, University of Bristol, Bristol, United Kingdom
| | - Ulrich Dirnagl
- Director, QUEST Center for Transforming Biomedical Research, Berlin Institute of Health & Department of Experimental Neurology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- Reader in Platelet Pharmacology, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Paul Garner
- Professor, and Director of the Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Stephen T. Holgate
- MRC Clinical Professor, Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
| | - David W. Howells
- Professor of Neuroscience and Brain Plasticity, Tasmanian School of Medicine, University of Tasmania, Hobart, Australia
| | - Natasha A. Karp
- Principal Scientist – Statistician & UK Team Lead, Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom
| | | | - Katie Lidster
- Programme Manager – Animal Welfare, NC3Rs, London, United Kingdom
| | | | - Malcolm Macleod
- Professor of Neurology and Translational Neuroscience, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Academic Lead for Research Improvement and Research Integrity, University of Edinburgh, Edinburgh, United Kingdom
| | - Esther J. Pearl
- Programme Manager – Experimental Design, NC3Rs, London, United Kingdom
| | - Ole H. Petersen
- Director of the Academia Europaea Knowledge Hub, Cardiff University, Cardiff, United Kingdom
| | - Frances Rawle
- Director of Policy, Ethics and Governance, Medical Research Council, London, United Kingdom
| | - Penny Reynolds
- Biostatistician, Statistics in Anesthesiology Research (STAR) Core & Research Assistant Professor, Department of Anesthesiology College of Medicine, University of Florida, Gainesville, Florida, United States of America
| | - Kieron Rooney
- Associate Professor, Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Emily S. Sena
- Stroke Association Kirby Laing Foundation Senior Non-Clinical Lecturer, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Shai D. Silberberg
- Director of Research Quality, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America
| | - Thomas Steckler
- Associate Director, BRQC Animal Welfare Strategy Lead, Janssen Pharmaceutica NV, Beerse, Belgium
| | - Hanno Würbel
- Professor for Animal Welfare, Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
18
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Exp Physiol 2020; 105:1459-1466. [PMID: 32666546 PMCID: PMC7610926 DOI: 10.1113/ep088870] [Citation(s) in RCA: 81] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the "ARRIVE Essential 10," which constitutes the minimum requirement, and the "Recommended Set," which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Collapse
Affiliation(s)
| | - Viki Hurst
- Science Manager – Experimental Design and Reporting, NC3Rs, London, United Kingdom
| | - Amrita Ahluwalia
- Professor of Vascular Pharmacology, Co-Director, The William Harvey Research Institute, London, United Kingdom
- Director of the Barts Cardiovascular CTU, Queen Mary University of London, London, United Kingdom
| | - Sabina Alam
- Director of Publishing Ethics and Integrity, Taylor & Francis Group, London, United Kingdom
| | - Marc T. Avey
- Lead Health Scientist, Health Science Practice, ICF, Durham, North Carolina, United States of America
| | - Monya Baker
- Senior Editor, Opinion, Nature, San Francisco, California, United States of America
| | - William J. Browne
- Professor of Statistics, School of Education, University of Bristol, Bristol, United Kingdom
| | - Alejandra Clark
- Senior Editor, Team Manager – Life Sciences, PLOS ONE, Cambridge, United Kingdom
| | - Innes C. Cuthill
- Professor of Behavioural Ecology, School of Biological Sciences, University of Bristol, Bristol, United Kingdom
| | - Ulrich Dirnagl
- Director, QUEST Center for Transforming Biomedical Research, Berlin Institute of Health & Department of Experimental Neurology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- Reader in Platelet Pharmacology, National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Paul Garner
- Professor, and Director of the Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Stephen T. Holgate
- MRC Clinical Professor, Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
| | - David W. Howells
- Professor of Neuroscience and Brain Plasticity, Tasmanian School of Medicine, University of Tasmania, Hobart, Australia
| | - Natasha A. Karp
- Principal Scientist – Statistician & UK Team Lead, Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom
| | | | - Katie Lidster
- Programme Manager – Animal Welfare, NC3Rs, London, United Kingdom
| | | | - Malcolm Macleod
- Professor of Neurology and Translational Neuroscience, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Academic Lead for Research Improvement and Research Integrity, University of Edinburgh, Edinburgh, United Kingdom
| | - Esther J. Pearl
- Programme Manager – Experimental Design, NC3Rs, London, United Kingdom
| | - Ole H. Petersen
- Director of the Academia Europaea Knowledge Hub, Cardiff University, Cardiff, United Kingdom
| | - Frances Rawle
- Director of Policy, Ethics and Governance, Medical Research Council, London, United Kingdom
| | - Penny Reynolds
- Biostatistician, Statistics in Anesthesiology Research (STAR) Core & Research Assistant Professor, Department of Anesthesiology College of Medicine University of Florida, Gainesville, Florida, United States of America
| | - Kieron Rooney
- Associate Professor, Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Emily S. Sena
- Stroke Association Kirby Laing Foundation Senior Non-Clinical Lecturer, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburg United Kingdom
| | - Shai D. Silberberg
- Director of Research Quality, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America
| | - Thomas Steckler
- Associate Director, BRQC Animal Welfare Strategy Lead, Janssen Pharmaceutica NV, Beerse, Belgium
| | - Hanno Würbel
- Professor for Animal Welfare, Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
19
|
Nguyen VA, Riddell N, Crewther SG, Faou P, Rajapaksha H, Howells DW, Hankey GJ, Wijeratne T, Ma H, Davis S, Donnan GA, Carey LM. Longitudinal Stroke Recovery Associated With Dysregulation of Complement System-A Proteomics Pathway Analysis. Front Neurol 2020; 11:692. [PMID: 32849183 PMCID: PMC7399641 DOI: 10.3389/fneur.2020.00692] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2020] [Accepted: 06/09/2020] [Indexed: 11/13/2022] Open
Abstract
Currently the longitudinal proteomic profile of post-ischemic stroke recovery is relatively unknown with few well-accepted biomarkers or understanding of the biological systems that underpin recovery. We aimed to characterize plasma derived biological pathways associated with recovery during the first year post event using a discovery proteomics workflow coupled with a topological pathway systems biology approach. Blood samples (n = 180, ethylenediaminetetraacetic acid plasma) were collected from a subgroup of 60 first episode stroke survivors from the Australian START study at 3 timepoints: 3-7 days (T1), 3-months (T2) and 12-months (T3) post-stroke. Samples were analyzed by liquid chromatography mass spectrometry using label-free quantification (data available at ProteomeXchange with identifier PXD015006). Differential expression analysis revealed that 29 proteins between T1 and T2, and 33 proteins between T1 and T3 were significantly different, with 18 proteins commonly differentially expressed across the two time periods. Pathway analysis was conducted using Gene Graph Enrichment Analysis on both the Kyoto Encyclopedia of Genes and Genomes and Reactome databases. Pathway analysis revealed that the significantly differentiated proteins between T1 and T2 were consistently found to belong to the complement pathway. Further correlational analyses utilized to examine the changes in regulatory effects of proteins over time identified significant inhibitory regulation of clusterin on complement component 9. Longitudinal post-stroke blood proteomics profiles suggest that the alternative pathway of complement activation remains in a state of higher activation from 3-7 days to 3 months post-stroke, while simultaneously being regulated by clusterin and vitronectin. These findings also suggest that post-stroke induced sterile inflammation and immunosuppression could inhibit recovery within the 3-month window post-stroke.
Collapse
Affiliation(s)
- Vinh A Nguyen
- Department of Occupational Therapy, La Trobe University, Bundoora, VIC, Australia.,Department of Psychology and Counselling, La Trobe University, Bundoora, VIC, Australia.,Neurorehabilitation and Recovery, Stroke, The Florey Institute of Neuroscience and Mental Health, Heidelberg, VIC, Australia.,Western Health, Department of Neurology, Sunshine, VIC, Australia
| | - Nina Riddell
- Department of Psychology and Counselling, La Trobe University, Bundoora, VIC, Australia
| | - Sheila G Crewther
- Department of Psychology and Counselling, La Trobe University, Bundoora, VIC, Australia
| | - Pierre Faou
- Department of Biochemistry and Genetics, La Trobe University, Bundoora, VIC, Australia
| | - Harinda Rajapaksha
- Department of Biochemistry and Genetics, La Trobe University, Bundoora, VIC, Australia
| | - David W Howells
- Medical Sciences Precinct, University of Tasmania, Hobart, TAS, Australia
| | - Graeme J Hankey
- Faculty of Health and Medical Sciences, Internal Medicine, University of Western Australia, Perth, WA, Australia.,Clinical Research, Harry Perkins Institute of Medical Research, Perth, WA, Australia
| | - Tissa Wijeratne
- Neurorehabilitation and Recovery, Stroke, The Florey Institute of Neuroscience and Mental Health, Heidelberg, VIC, Australia.,Department of Medicine, The University of Melbourne, Sunshine, VIC, Australia
| | - Henry Ma
- Monash Health, Neurology and Stroke, Clayton, VIC, Australia
| | - Stephen Davis
- Department of Neurology, Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Geoffrey A Donnan
- Department of Neurology, Royal Melbourne Hospital, Parkville, VIC, Australia
| | - Leeanne M Carey
- Department of Occupational Therapy, La Trobe University, Bundoora, VIC, Australia.,Neurorehabilitation and Recovery, Stroke, The Florey Institute of Neuroscience and Mental Health, Heidelberg, VIC, Australia
| |
Collapse
|
20
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br J Pharmacol 2020; 177:3617-3624. [PMID: 32662519 PMCID: PMC7393194 DOI: 10.1111/bph.15193] [Citation(s) in RCA: 292] [Impact Index Per Article: 73.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the "ARRIVE Essential 10," which constitutes the minimum requirement, and the "Recommended Set," which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration (E&E) document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Collapse
Affiliation(s)
| | | | - Amrita Ahluwalia
- The William Harvey Research Institute, London, UK
- Barts Cardiovascular CTU, Queen Mary University of London, London, UK
| | | | - Marc T Avey
- Health Science Practice, ICF, Durham, North Carolina, USA
| | | | | | | | - Innes C Cuthill
- School of Biological Sciences, University of Bristol, Bristol, UK
| | - Ulrich Dirnagl
- QUEST Center for Transforming Biomedical Research, Berlin Institute of Health & Department of Experimental Neurology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Paul Garner
- Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Stephen T Holgate
- Clinical and Experimental Sciences, University of Southampton, Southampton, UK
| | - David W Howells
- Tasmanian School of Medicine, University of Tasmania, Hobart, Australia
| | - Natasha A Karp
- Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK
| | | | | | | | | | | | - Ole H Petersen
- Academia Europaea Knowledge Hub, Cardiff University, Cardiff, UK
| | | | - Penny Reynolds
- Statistics in Anesthesiology Research (STAR) Core & Research Assistant Professor, Department of Anesthesiology, College of Medicine, University of Florida, Gainesville, Florida, USA
| | - Kieron Rooney
- Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | | | - Shai D Silberberg
- National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA
| | | | - Hanno Würbel
- Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
21
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Wuerbel H. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Sci 2020; 4:e100115. [PMID: 34095516 PMCID: PMC7610906 DOI: 10.1136/bmjos-2020-100115] [Citation(s) in RCA: 100] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into two sets, the 'ARRIVE Essential 10', which constitutes the minimum requirement, and the 'Recommended Set', which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Collapse
Affiliation(s)
| | - Viki Hurst
- Experimental Design and Reporting, NC3Rs, London, UK
| | - Amrita Ahluwalia
- William Harvey Research Institute, London, UK
- Queen Mary University of London, London, UK
| | | | | | - Monya Baker
- Opinion, Nature, San Francisco, California, USA
| | | | | | - Innes C Cuthill
- School of Biological Sciences, University of Bristol, Bristol, UK
| | - Ulrich Dirnagl
- Quest Center for Transforming Biomedical Research, Berlin Institute of Health, Berlin, Germany
- Department of Experimental Neurology, Charite Universitatsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Paul Garner
- Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Stephen T Holgate
- Clinical and Experimental Sciences, University of Southampton, Southampton, Hampshire, UK
| | - David W Howells
- Tasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Natasha A Karp
- Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca PLC, Cambridge, Cambridgeshire, UK
| | | | | | | | - Malcolm Macleod
- Academic Lead for Research Improvement and Research Integrity, University of Edinburgh, Edinburgh, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | - Ole H Petersen
- Academia Europaea Knowledge Hub, Cardiff University, Cardiff, South Glamorgan, UK
| | - Frances Rawle
- Policy, Ethics and Governance, Medical Research Council, London, UK
| | - Penny Reynolds
- Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida, USA
| | - Kieron Rooney
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Emily S Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Shai D Silberberg
- Research Quality, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA
| | | | - Hanno Wuerbel
- Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
22
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. BMC Vet Res 2020; 16:242. [PMID: 32660541 PMCID: PMC7359286 DOI: 10.1186/s12917-020-02451-y] [Citation(s) in RCA: 115] [Impact Index Per Article: 28.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the "ARRIVE Essential 10," which constitutes the minimum requirement, and the "Recommended Set," which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Collapse
Affiliation(s)
| | - Viki Hurst
- Experimental Design and Reporting, NC3Rs, London, UK
| | - Amrita Ahluwalia
- The William Harvey Research Institute, London, UK
- Barts Cardiovascular CTU, Queen Mary University of London, London, UK
| | - Sabina Alam
- Publishing Ethics and Integrity, Taylor & Francis Group, London, UK
| | - Marc T Avey
- Health Science Practice, ICF, Durham, North Carolina, USA
| | - Monya Baker
- Opinion, Nature, San Francisco, California, USA
| | | | | | - Innes C Cuthill
- School of Biological Sciences, University of Bristol, Bristol, UK
| | - Ulrich Dirnagl
- QUEST Center for Transforming Biomedical Research, Berlin Institute of Health & Department of Experimental Neurology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Paul Garner
- Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Stephen T Holgate
- Clinical and Experimental Sciences, University of Southampton, Southampton, UK
| | - David W Howells
- Tasmanian School of Medicine, University of Tasmania, Hobart, Australia
| | - Natasha A Karp
- Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK
| | | | | | | | - Malcolm Macleod
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | - Ole H Petersen
- Academia Europaea Knowledge Hub, Cardiff University, Cardiff, UK
| | - Frances Rawle
- Policy, Ethics and Governance, Medical Research Council, London, UK
| | - Penny Reynolds
- Statistics in Anesthesiology Research (STAR), Department of Anesthesiology College of Medicine, University of Florida, Gainesville, Florida, USA
| | - Kieron Rooney
- Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Emily S Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Shai D Silberberg
- Research Quality, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
| | | | - Hanno Würbel
- Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
23
|
Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Hurst V, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 2020; 18:e3000411. [PMID: 32663221 PMCID: PMC7360025 DOI: 10.1371/journal.pbio.3000411] [Citation(s) in RCA: 903] [Impact Index Per Article: 225.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Improving the reproducibility of biomedical research is a major challenge. Transparent and accurate reporting is vital to this process; it allows readers to assess the reliability of the findings and repeat or build upon the work of other researchers. The ARRIVE guidelines (Animal Research: Reporting In Vivo Experiments) were developed in 2010 to help authors and journals identify the minimum information necessary to report in publications describing in vivo experiments. Despite widespread endorsement by the scientific community, the impact of ARRIVE on the transparency of reporting in animal research publications has been limited. We have revised the ARRIVE guidelines to update them and facilitate their use in practice. The revised guidelines are published alongside this paper. This explanation and elaboration document was developed as part of the revision. It provides further information about each of the 21 items in ARRIVE 2.0, including the rationale and supporting evidence for their inclusion in the guidelines, elaboration of details to report, and examples of good reporting from the published literature. This document also covers advice and best practice in the design and conduct of animal studies to support researchers in improving standards from the start of the experimental design process through to publication.
Collapse
Affiliation(s)
| | - Amrita Ahluwalia
- The William Harvey Research Institute, London, United Kingdom
- Barts Cardiovascular CTU, Queen Mary University of London, London, United Kingdom
| | - Sabina Alam
- Taylor & Francis Group, London, United Kingdom
| | - Marc T. Avey
- Health Science Practice, ICF, Durham, North Carolina, United States of America
| | - Monya Baker
- Nature, San Francisco, California, United States of America
| | | | | | - Innes C. Cuthill
- School of Biological Sciences, University of Bristol, Bristol, United Kingdom
| | - Ulrich Dirnagl
- QUEST Center for Transforming Biomedical Research, Berlin Institute of Health & Department of Experimental Neurology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Paul Garner
- Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Stephen T. Holgate
- Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
| | - David W. Howells
- Tasmanian School of Medicine, University of Tasmania, Hobart, Australia
| | | | - Natasha A. Karp
- Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom
| | | | | | | | - Malcolm Macleod
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | | | - Ole H. Petersen
- Academia Europaea Knowledge Hub, Cardiff University, Cardiff, United Kingdom
| | | | - Penny Reynolds
- Statistics in Anesthesiology Research (STAR) Core, Department of Anesthesiology, College of Medicine, University of Florida, Gainesville, Florida, United States of America
| | - Kieron Rooney
- Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Emily S. Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Shai D. Silberberg
- National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America
| | | | - Hanno Würbel
- Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
24
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol 2020; 18:e3000410. [PMID: 32663219 PMCID: PMC7360023 DOI: 10.1371/journal.pbio.3000410] [Citation(s) in RCA: 1977] [Impact Index Per Article: 494.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the "ARRIVE Essential 10," which constitutes the minimum requirement, and the "Recommended Set," which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration (E&E) document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Collapse
Affiliation(s)
| | | | - Amrita Ahluwalia
- The William Harvey Research Institute, London, United Kingdom
- Barts Cardiovascular CTU, Queen Mary University of London, London, United Kingdom
| | - Sabina Alam
- Taylor & Francis Group, London, United Kingdom
| | - Marc T. Avey
- Health Science Practice, ICF, Durham, North Carolina, United States of America
| | - Monya Baker
- Nature, San Francisco, California, United States of America
| | | | | | - Innes C. Cuthill
- School of Biological Sciences, University of Bristol, Bristol, United Kingdom
| | - Ulrich Dirnagl
- QUEST Center for Transforming Biomedical Research, Berlin Institute of Health & Department of Experimental Neurology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Emerson
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Paul Garner
- Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Stephen T. Holgate
- Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
| | - David W. Howells
- Tasmanian School of Medicine, University of Tasmania, Hobart, Australia
| | - Natasha A. Karp
- Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom
| | | | | | | | - Malcolm Macleod
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | | | - Ole H. Petersen
- Academia Europaea Knowledge Hub, Cardiff University, Cardiff, United Kingdom
| | | | - Penny Reynolds
- Statistics in Anesthesiology Research (STAR) Core, Department of Anesthesiology, College of Medicine, University of Florida, Gainesville, Florida, United States of America
| | - Kieron Rooney
- Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Emily S. Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Shai D. Silberberg
- National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America
| | | | - Hanno Würbel
- Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
25
|
Premilovac D, Blackwood SJ, Ramsay CJ, Keske MA, Howells DW, Sutherland BA. Transcranial contrast-enhanced ultrasound in the rat brain reveals substantial hyperperfusion acutely post-stroke. J Cereb Blood Flow Metab 2020; 40:939-953. [PMID: 32063081 PMCID: PMC7181087 DOI: 10.1177/0271678x20905493] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Direct and real-time assessment of cerebral hemodynamics is key to improving our understanding of cerebral blood flow regulation in health and disease states such as stroke. While a number of sophisticated imaging platforms enable assessment of cerebral perfusion, most are limited either spatially or temporally. Here, we applied transcranial contrast-enhanced ultrasound (CEU) to measure cerebral perfusion in real-time through the intact rat skull before, during and after ischemic stroke, induced by intraluminal filament middle cerebral artery occlusion (MCAO). We demonstrate expected decreases in cortical and striatal blood volume, flow velocity and perfusion during MCAO. After filament retraction, blood volume and perfusion increased two-fold above baseline, indicative of acute hyperperfusion. Adjacent brain regions to the ischemic area and the contralateral hemisphere had increased blood volume during MCAO. We assessed our data using wavelet analysis to demonstrate striking vasomotion changes in the ischemic and contralateral cortices during MCAO and reperfusion. In conclusion, we demonstrate the application of CEU for real-time assessment of cerebral hemodynamics and show that the ischemic regions exhibit striking hyperemia post-MCAO. Whether this post-stoke hyperperfusion is sustained long-term and contributes to stroke severity is not known.
Collapse
Affiliation(s)
- Dino Premilovac
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Sarah J Blackwood
- Åstrand Laboratory of Work Physiology, Swedish School of Sport and Health Sciences, GIH, Stockholm, Sweden
| | - Ciaran J Ramsay
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Michelle A Keske
- Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia
| | - David W Howells
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Brad A Sutherland
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
26
|
Liu Y, Michalska AE, Dottori M, Eaton E, Courtney JM, Antonic A, Howells DW. Differential susceptibility of human neural progenitors and neurons to ischaemic injury. Brain Res Bull 2019; 156:25-32. [PMID: 31837459 DOI: 10.1016/j.brainresbull.2019.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2019] [Revised: 11/10/2019] [Accepted: 12/10/2019] [Indexed: 11/16/2022]
Abstract
BACKGROUND Neuroprotection for stroke has shown great promise but has had little translational success. Developing drugs for humans logically requires human tissue evaluation. Human embryonic stem cell (hESC)-derived neuronal cultures at different developmental stages were subject to oxygen glucose deprivation (OGD) to determine how developing maturity altered response to ischemic injury. METHODS H9 hESCs were induced by Noggin to generate neural progenitors (NPs) and highly arbourised structurally complex neurons. They were both subjected to OGD or OGD with reoxygenation (OGD-R) for 1-6 h.Outcome was assessed by measures of cell death, survival and morphology. RESULTS NPs did not die after OGD but experienced progressive loss of metabolic activity. Highly arbourised neurons showed minimal cell death initially but 44 % and 78 % died after 4 and 6 h OGD. Metabolic dysfunction was greater in these more mature neurons (∼70 %) than in NPs and evident after 1 h OGD, before detection of neuronal death at 4 h. OGD-R salvaged metabolic activity but not cell death in mature neurons. In NPs there was little metabolic salvage and cell death was induced (50 % and 65 % at 4 and 6 h OGD-R, respectively). CONCLUSIONS Highly arbourised neurons are more sensitive to ischaemic injury than NPs which did however develop marked vulnerability to prolonged injury with reoxygenation. These observations imply that therapeutic potential may be highly dependent of the developmental state of the neurons we aim to protect.
Collapse
Affiliation(s)
- Ye Liu
- Department of Neurology, Huashan Hospital, Shanghai, 200040, China; Department of Neurology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, 200433, China
| | - Anna E Michalska
- Stem Cell Core Facility, Stem Cells Australia, The University of Melbourne, Victoria, 3010, Australia
| | - Mirella Dottori
- Illawarra Health and Medical Research Institute, University of Wollongong, NSW, 2522 Australia
| | - Emma Eaton
- School of Medicine, University of Tasmania, Hobart, Tasmania, 7001, Australia
| | - Jo-Maree Courtney
- School of Medicine, University of Tasmania, Hobart, Tasmania, 7001, Australia
| | - Ana Antonic
- Department of Neuroscience, Central Clinical School, Monash University, The Alfred Centre, VIC 3004, Australia
| | - David W Howells
- School of Medicine, University of Tasmania, Hobart, Tasmania, 7001, Australia.
| |
Collapse
|
27
|
Landowski LM, Niego B, Sutherland BA, Hagemeyer CE, Howells DW. Applications of Nanotechnology in the Diagnosis and Therapy of Stroke. Semin Thromb Hemost 2019; 46:592-605. [PMID: 31858516 DOI: 10.1055/s-0039-3399568] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Stroke is a leading cause of death and disability worldwide. The classification of stroke subtypes is difficult but critical for the prediction of clinical course and patient management, and limited treatment options are available. There is an urgent need for improvements in both diagnosis and therapy. Strokes have rapidly evolving phases of damage involving unique compartments of the brain, which imposes severe limitations for current diagnostic and treatment procedures. The rapid development of nanotechnology in other areas of modern medicine has ignited a widespread interest in its potential for the field of stroke. An important feature of nanoparticles is the relative ease in which their structures and surface chemistries can be modified for specific and potentially multiple, simultaneous purposes. Nanoparticles can be synthesized to carry and deliver therapeutics to specific cellular or subcellular compartments; they can be engineered to provide enhanced contrast for imaging based on the detection of changes in the blood flow; or possess ligand-specific chemistries which can facilitate diagnosis and monitor the treatment response. More specifically for a stroke, nanoparticles can be engineered to release their payload in response to the distinct extracellular processes occurring around the clot and in the ischemic penumbra, as well as aid in the detection of pathological hallmarks present at various stages of stroke progression. These capacities allow targeted release of disease-modifying agents in the affected brain tissue, increasing treatment efficacy, and limiting unwanted side effects. While nanospheres, liposomes, and mesoporous nanostructures all emerge as future prospects for stroke treatment and diagnosis, much of this potential is yet to be clinically realized. This review outlines aspects of nanotechnology identified as having potential to revolutionize the field of stroke.
Collapse
Affiliation(s)
- Lila M Landowski
- Stroke Research Unit, School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Be'eri Niego
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia
| | - Brad A Sutherland
- Stroke Research Unit, School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Christoph E Hagemeyer
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia
| | - David W Howells
- Stroke Research Unit, School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
28
|
Brown LS, Foster CG, Courtney JM, King NE, Howells DW, Sutherland BA. Pericytes and Neurovascular Function in the Healthy and Diseased Brain. Front Cell Neurosci 2019; 13:282. [PMID: 31316352 PMCID: PMC6611154 DOI: 10.3389/fncel.2019.00282] [Citation(s) in RCA: 204] [Impact Index Per Article: 40.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 06/11/2019] [Indexed: 12/11/2022] Open
Abstract
Pericytes are multi-functional cells embedded within the walls of capillaries throughout the body, including the brain. Pericytes were first identified in the 1870s, but little attention was paid to them during the following century. More recently, numerous vascular functions of pericytes have been identified including regulation of cerebral blood flow, maintenance of the blood-brain barrier (BBB), and control of vascular development and angiogenesis. Pericytes can also facilitate neuroinflammatory processes and possess stem cell-like properties. Pericytes form part of the neurovascular unit (NVU), a collection of cells that control interactions between neurons and the cerebral vasculature to meet the energy demands of the brain. Pericyte structure, expression profile, and function in the brain differ depending on their location along the vascular bed. Until recently, it has been difficult to accurately define the sub-types of pericytes, or to specifically target pericytes with pharmaceutical agents, but emerging techniques both in vitro and in vivo will improve investigation of pericytes and allow for the identification of their possible roles in diseases. Pericyte dysfunction is increasingly recognized as a contributor to the progression of vascular diseases such as stroke and neurodegenerative diseases such as Alzheimer’s disease. The therapeutic potential of pericytes to repair cerebral blood vessels and promote angiogenesis due to their ability to behave like stem cells has recently been brought to light. Here, we review the history of pericyte research, the present techniques used to study pericytes in the brain, and current research advancements to characterize and therapeutically target pericytes in the future.
Collapse
Affiliation(s)
- Lachlan S Brown
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
| | - Catherine G Foster
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
| | - Jo-Maree Courtney
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
| | - Natalie E King
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
| | - David W Howells
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
| | - Brad A Sutherland
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
| |
Collapse
|
29
|
Watzlawick R, Antonic A, Sena ES, Kopp MA, Rind J, Dirnagl U, Macleod M, Howells DW, Schwab JM. Outcome heterogeneity and bias in acute experimental spinal cord injury: A meta-analysis. Neurology 2019; 93:e40-e51. [PMID: 31175207 DOI: 10.1212/wnl.0000000000007718] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Accepted: 02/11/2019] [Indexed: 01/18/2023] Open
Abstract
OBJECTIVE To determine whether and to what degree bias and underestimated variability undermine the predictive value of preclinical research for clinical translation. METHODS We investigated experimental spinal cord injury (SCI) studies for outcome heterogeneity and the impact of bias. Data from 549 preclinical SCI studies including 9,535 animals were analyzed with meta-regression to assess the effect of various study characteristics and the quality of neurologic recovery. RESULTS Overall, the included interventions reported a neurobehavioral outcome improvement of 26.3% (95% confidence interval 24.3-28.4). Response to treatment was dependent on experimental modeling paradigms (neurobehavioral score, site of injury, and animal species). Applying multiple outcome measures was consistently associated with smaller effect sizes compared with studies applying only 1 outcome measure. More than half of the studies (51.2%) did not report blinded assessment, constituting a likely source of evaluation bias, with an overstated effect size of 7.2%. Assessment of publication bias, which extrapolates to identify likely missing data, suggested that between 2% and 41% of experiments remain unpublished. Inclusion of these theoretical missing studies suggested an overestimation of efficacy, reducing the effect sizes by between 0.9% and 14.3%. CONCLUSIONS We provide empirical evidence of prevalent bias in the design and reporting of experimental SCI studies, resulting in overestimation of the effectiveness. Bias compromises the internal validity and jeopardizes the successful translation of SCI therapies from the bench to bedside.
Collapse
Affiliation(s)
- Ralf Watzlawick
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - Ana Antonic
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - Emily S Sena
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - Marcel A Kopp
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - Julian Rind
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - Ulrich Dirnagl
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - Malcolm Macleod
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - David W Howells
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus
| | - Jan M Schwab
- From Charité-Universitätsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité-Universitätsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.), Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and Clinical Neurosciences (E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité-Universitätsmedizin, Berlin, Germany; German Center for Neurodegenerative Diseases (U.D.), Bonn; Berlin Institute of Health (M.A.K., U.D.), Germany; University of Tasmania (D.W.H.), School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Australia; Department of Neurology (J.M.S.), Spinal Cord Injury Medicine (Paraplegiology), and Belford Center for Spinal Cord Injury (J.M.S.), Departments of Neuroscience and Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus.
| |
Collapse
|
30
|
Liu Y, Eaton ED, Wills TE, McCann SK, Antonic A, Howells DW. Human Ischaemic Cascade Studies Using SH-SY5Y Cells: a Systematic Review and Meta-Analysis. Transl Stroke Res 2018; 9:564-574. [PMID: 29572690 PMCID: PMC6208743 DOI: 10.1007/s12975-018-0620-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 03/03/2018] [Accepted: 03/06/2018] [Indexed: 01/21/2023]
Abstract
Low translational yield for stroke may reflect the focus of discovery science on rodents rather than humans. Just how little is known about human neuronal ischaemic responses is confirmed by systematic review and meta-analysis revealing that data for the most commonly used SH-SY5Y human cells comprises only 84 papers. Oxygen-glucose deprivation, H2O2, hypoxia, glucose-deprivation and glutamate excitotoxicity yielded - 58, - 61, - 29, - 45 and - 49% injury, respectively, with a dose-response relationship found only for H2O2 injury (R2 = 29.29%, p < 0.002). Heterogeneity (I2 = 99.36%, df = 132, p < 0.0001) was largely attributable to the methods used to detect injury (R2 = 44.77%, p < 0.000) with cell death assays detecting greater injury than survival assays (- 71 vs - 47%, R2 = 28.64%, p < 0.000). Seventy-four percent of publications provided no description of differentiation status, but in the 26% that did, undifferentiated cells were susceptible to greater injury (R2 = 4.13%, p < 0.047). One hundred and sixty-nine interventions improved average survival by 34.67% (p < 0.0001). Eighty-eight comparisons using oxygen-glucose deprivation found both benefit and harm, but studies using glutamate and H2O2 injury reported only improvement. In studies using glucose deprivation, intervention generally worsened outcome. There was insufficient data to rank individual interventions, but of the studies reporting greatest improvement (> 90% effect size), 7/13 were of herbal medicine constituents (24.85% of the intervention dataset). We conclude that surprisingly little is known of the human neuronal response to ischaemic injury, and that the large impact of methodology on outcome indicates that further model validation is required. Lack of evidence for randomisation, blinding or power analysis suggests that the intervention data is at substantial risk of bias.
Collapse
Affiliation(s)
- Ye Liu
- The Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, The University of Melbourne, Melbourne, VIC, 3052, Australia
| | - Emma D Eaton
- School of Medicine, Faculty of Health, University of Tasmania, Medical Sciences Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia
| | - Taryn E Wills
- Melbourne Brain Centre, Florey Institute of Neuroscience and Mental Health, 245 Burgundy St, Heidelberg, VIC, 3084, Australia
| | - Sarah K McCann
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK
| | - Ana Antonic
- Department of Neuroscience, Monash University, Melbourne, VIC, 3004, Australia
| | - David W Howells
- School of Medicine, Faculty of Health, University of Tasmania, Medical Sciences Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia.
- School of Medicine, Faculty of Health, University of Tasmania, Medical Sciences Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia.
| |
Collapse
|
31
|
Beard DJ, Hadley G, Thurley N, Howells DW, Sutherland BA, Buchan AM. The effect of rapamycin treatment on cerebral ischemia: A systematic review and meta-analysis of animal model studies. Int J Stroke 2018; 14:137-145. [PMID: 30489210 DOI: 10.1177/1747493018816503] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Amplifying endogenous neuroprotective mechanisms is a promising avenue for stroke therapy. One target is mammalian target of rapamycin (mTOR), a serine/threonine kinase regulating cell proliferation, cell survival, protein synthesis, and autophagy. Animal studies investigating the effect of rapamycin on mTOR inhibition following cerebral ischemia have shown conflicting results. AIM To conduct a systematic review and meta-analysis evaluating the effectiveness of rapamycin in reducing infarct volume in animal models of ischemic stroke. SUMMARY OF REVIEW Our search identified 328 publications. Seventeen publications met inclusion criteria (52 comparisons: 30 reported infarct size and 22 reported neurobehavioral score). Study quality was modest (median 4 of 9) with no evidence of publication bias. The point estimate for the effect of rapamycin was a 21.6% (95% CI, 7.6%-35.7% p < 0.01) improvement in infarct volume and 30.5% (95% CI 17.2%-43.8%, p < 0.0001) improvement in neuroscores. Effect sizes were greatest in studies using lower doses of rapamycin. CONCLUSION Low-dose rapamycin treatment may be an effective therapeutic option for stroke. Modest study quality means there is a potential risk of bias. We recommend further high-quality preclinical studies on rapamycin in stroke before progressing to clinical trials.
Collapse
Affiliation(s)
- Daniel J Beard
- 1 Acute Stroke Programme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Gina Hadley
- 1 Acute Stroke Programme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.,2 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Neal Thurley
- 3 Bodleian Healthcare Libraries, University of Oxford, Oxford, UK
| | - David W Howells
- 4 School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia
| | - Brad A Sutherland
- 4 School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia
| | - Alastair M Buchan
- 1 Acute Stroke Programme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.,5 Medical Sciences Division, University of Oxford, Oxford, UK.,6 Acute Vascular Imaging Centre, University of Oxford, Oxford University Hospitals, Oxford, UK
| |
Collapse
|
32
|
Liu Y, Antonic A, Yang X, Korte N, Lim K, Michalska AE, Dottori M, Howells DW. Derivation of phenotypically diverse neural culture from hESC by combining adherent and dissociation methods. J Neurosci Methods 2018; 308:286-293. [PMID: 30003885 DOI: 10.1016/j.jneumeth.2018.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Revised: 07/05/2018] [Accepted: 07/05/2018] [Indexed: 11/18/2022]
Abstract
BACKGROUND Differentiation of human embryonic stem cells (hESCs) into distinct neural lineages has been widely studied. However, preparation of mixed yet neurochemically mature populations, for the study of neurological diseases involving mixed cell types has received less attention. NEW METHOD We combined two commonly used differentiation methods to provide robust and reproducible cultures in which a mixture of primarily GABAergic and Glutamatergic neurons was obtained. Detailed characterisation by immunocytochemistry (ICC) and quantitative real-time PCR (qPCR) assessed the neurochemical phenotype, and the maturation state of these neurons. RESULTS We found that once neurospheres (NSs) had attached to the culture plates, proliferation of neural stem cell was suppressed. Neuronal differentiation and synaptic development then occurred after 21 days in vitro (DIV). By 49DIV, there were large numbers of neurochemically and structurally mature neurons. The qPCR studies indicated that expression of GABAergic genes increased the most (93.3-fold increase), followed by glutamatergic (51-fold increase), along with smaller changes in expression of cholinergic (3-fold increase) and dopaminergic genes (6-fold increase), as well as a small change in glial cell marker expression (5-fold increase). COMPARISON WITH EXISTING METHOD (S) Existing methods isolate hESC-derived neural progenitors for onward differentiation to mature neurons using either migration or dissociative paradigms. These give poor survival or yield. By combining these approaches, we obtain high yields of morphologically and neurochemically mature neurons. These can be maintained in culture for extended periods. CONCLUSION Our method provides a novel, effective and robust neural culture system with structurally and neurochemically mature cell populations and neural networks, suitable for studying a range of neurological diseases from a human perspective.
Collapse
Affiliation(s)
- Ye Liu
- Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, The University of Melbourne, Victoria, 3010, Australia; Department of Neurology, Fudan University, Huashan Hospital, Shanghai, 200040, China
| | - Ana Antonic
- Department of Neuroscience, Central Clinical School, Monash University, The Alfred Centre, VIC, 3004, Australia
| | - Xuan Yang
- Institute for Geriatrics and Rehabilitation, Beijing Geriatric Hospital, Beijing, 100095, China
| | - Nils Korte
- Department of Neuroscience, Physiology and Pharmacology, University College London, Gower Street, London, WC1E6BT, UK
| | - Katherine Lim
- Stem Cell Core Facility, Stem Cells Australia, The University of Melbourne, Victoria, 3010, Australia
| | - Anna E Michalska
- Stem Cell Core Facility, Stem Cells Australia, The University of Melbourne, Victoria, 3010, Australia
| | - Mirella Dottori
- Illawarra Health and Medical Research Institute Centre for Molecular and Medical Bioscience Building 32, University of Wollongong, NSW, 2522 Australia
| | - David W Howells
- School of Medicine, University of Tasmania, Hobart, Tasmania, 7001, Australia.
| |
Collapse
|
33
|
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Altman DG, Avey MT, Baker M, Browne W, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Howells DW, Karp NA, MacCallum CJ, Macleod M, Petersen O, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H, Holgate ST. Revision of the ARRIVE guidelines: rationale and scope. BMJ Open Sci 2018; 2:e000002. [PMID: 33954268 PMCID: PMC7610716 DOI: 10.1136/bmjos-2018-000002] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 04/11/2018] [Accepted: 05/02/2018] [Indexed: 01/24/2023] Open
Abstract
In 2010, the NC3Rs published the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines to improve the reporting of animal research. Despite considerable levels of support from the scientific community, the impact on the quality of reporting in animal research publications has been limited. This position paper highlights the strategy of an expert working group established to revise the guidelines and facilitate their uptake. The group's initial work will focus on three main areas: prioritisation of the ARRIVE items into a tiered system, development of an explanation and elaboration document, and revision of specific items.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Ulrich Dirnagl
- QUEST–Center for Transforming Biomedical Research, Berlin Institute of Health (BIH), Berlin, Germany
| | | | - Paul Garner
- Liverpool School of Tropical Medicine, Liverpool, UK
| | | | - Natasha A Karp
- Quantitative Biology, Discovery Science, IMED Biotech Unit, Cambridge, UK
| | | | - Malcolm Macleod
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | | | | | - Kieron Rooney
- University of Sydney, Sydney, New South Wales, Australia
| | - Emily S Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Shai D Silberberg
- National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA
| | | | | | | |
Collapse
|
34
|
Antonic A, Dottori M, Macleod MR, Donnan GA, Howells DW. NXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons. J Stroke Cerebrovasc Dis 2018; 27:2158-2165. [PMID: 29673616 DOI: 10.1016/j.jstrokecerebrovasdis.2018.03.015] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 03/02/2018] [Accepted: 03/15/2018] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Developing new medicines is a complex process where understanding the reasons for both failure and success takes us forward. One gap in our understanding of most candidate stroke drugs before clinical trial is whether they have a protective effect on human tissues. NXY-059 is a spin-trap reagent hypothesized to have activity against the damaging oxidative biology which accompanies ischemic stroke. Re-examination of the preclinical in vivo dataset for this agent in the wake of the failed SAINT-II RCT highlighted the presence of a range of biases leading to overestimation of the magnitude of NXY-059's effects in laboratory animals. Therefore, NXY-059 seemed an ideal candidate to evaluate in human neural tissues to determine whether human tissue testing might improve screening efficiency. MATERIALS AND METHODS The aim of this randomized and blinded study was to assess the effects of NXY-059 on human stem cell-derived neurons in the presence of ischemia-like injury induced by oxygen glucose deprivation or oxidative stress induced by hydrogen peroxide or sodium nitroprusside. RESULTS In MTT assays of cell survival, lactate dehydrogenase assays of total cell death and terminal deoxynucleotidyl transferase dUTP nick end labeling staining of apoptotic-like cell death, NXY-059 at concentrations ranging from 1 µm to 1 mm was completely without activity. Conversely an antioxidant cocktail comprising 100 µm each of ascorbate, reduced glutathione, and dithiothreitol used as a positive control provided marked neuronal protection in these assays. CONCLUSION These findings support our hypothesis that stroke drug screening in human neural tissues will be of value and provides an explanation for the failure of NXY-059 as a human stroke drug.
Collapse
Affiliation(s)
- Ana Antonic
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Victoria, Australia; Department of Neuroscience, Central Clinical School, Monash University, The Alfred Centre, Victoria, Australia
| | - Mirella Dottori
- Illawarra Health and Medical Research Institute, Centre for Molecular and Medical Bioscience, University of Wollongong, Wollongong, New South Wales, Australia
| | - Malcolm R Macleod
- Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK
| | - Geoffrey A Donnan
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Victoria, Australia
| | - David W Howells
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Victoria, Australia; University of Tasmania, School of Medicine, Faculty of Health, Hobart, Tasmania, Australia.
| |
Collapse
|
35
|
Simonato M, Iyengar S, Brooks-Kayal A, Collins S, Depaulis A, Howells DW, Jensen F, Liao J, Macleod MR, Patel M, Potschka H, Walker M, Whittemore V, Sena ES. Identification and characterization of outcome measures reported in animal models of epilepsy: Protocol for a systematic review of the literature-A TASK2 report of the AES/ILAE Translational Task Force of the ILAE. Epilepsia 2017; 58 Suppl 4:68-77. [PMID: 29105071 DOI: 10.1111/epi.13908] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/23/2017] [Indexed: 11/29/2022]
Abstract
Current antiseizure therapy is ineffective in approximately one third of people with epilepsy and is often associated with substantial side effects. In addition, most current therapeutic paradigms offer treatment, but not cure, and no therapies are able to modify the underlying disease, that is, can prevent or halt the process of epileptogenesis or alleviate the cognitive and psychiatric comorbidities. Preclinical research in the field of epilepsy has been extensive, but unfortunately, not all the animal models being used have been validated for their predictive value. The overall goal of TASK2 of the AES/ILAE Translational Task Force is to organize and coordinate systematic reviews on selected topics regarding animal research in epilepsy. Herein we describe our strategy. In the first part of the paper we provide an overview of the usefulness of systematic reviews and meta-analysis for preclinical research and explain the essentials for their conduct. Then we describe in detail the protocol for a first systematic review, which will focus on the identification and characterization of outcome measures reported in animal models of epilepsy. The specific goals of this study are to define systematically the phenotypic characteristics of the most commonly used animal models, and to effectively compare these with the manifestations of human epilepsy. This will provide epilepsy researchers with detailed information on the strengths and weaknesses of epilepsy models, facilitating their refinement and future research. Ultimately, this could lead to a refined use of relevant models for understanding the mechanism(s) of the epilepsies and developing novel therapies.
Collapse
Affiliation(s)
- Michele Simonato
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy.,University Vita-Salute San Raffaele, Milan, Italy
| | - Sloka Iyengar
- Department of Neurology, Montefiore Medical Center, Bronx, New York, U.S.A
| | - Amy Brooks-Kayal
- Department of Pediatrics, Neurology and Pharmaceutical Sciences, Children's Hospital of Colorado, University of Colorado, Aurora, Colorado, U.S.A
| | | | - Antoine Depaulis
- Grenoble Institute for Neuroscience-INSERM U1216, University Grenoble Alpes, Grenoble, France
| | - David W Howells
- School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Frances Jensen
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A
| | - Jing Liao
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Malcolm R Macleod
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Manisha Patel
- Department of Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, U.S.A
| | - Heidrun Potschka
- Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University (LMU), Munich, Germany
| | - Matthew Walker
- Institute of Neurology, University College of London, London, United Kingdom
| | - Vicky Whittemore
- National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, U.S.A
| | - Emily S Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| |
Collapse
|
36
|
Rewell SSJ, Jeffreys AL, Sastra SA, Cox SF, Fernandez JA, Aleksoska E, van der Worp HB, Churilov L, Macleod MR, Howells DW. Hypothermia revisited: Impact of ischaemic duration and between experiment variability. J Cereb Blood Flow Metab 2017; 37:3380-3390. [PMID: 28084873 PMCID: PMC5624387 DOI: 10.1177/0271678x16688704] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
To assess the true effect of novel therapies for ischaemic stroke, a positive control that can validate the experimental model and design is vital. Hypothermia may be a good candidate for such a positive control, given the convincing body of evidence from animal models of ischaemic stroke. Taking conditions under which substantial efficacy had been seen in a meta-analysis of hypothermia for focal ischaemia in animal models, we undertook three randomised and blinded studies examining the effect of hypothermia induced immediately following the onset of middle cerebral artery occlusion on infarct volume in rats (n = 15, 23, 264). Hypothermia to a depth of 33℃ and maintained for 130 min significantly reduced infarct volume compared to normothermia treatment (by 27-63%) and depended on ischaemic duration (F(3,244) = 21.242, p < 0.05). However, the protective effect varied across experiments with differences in both the size of the infarct observed in normothermic controls and the time to reach target temperature. Our results highlight the need for sample size and power calculations to take into account variations between individual experiments requiring induction of focal ischaemia.
Collapse
Affiliation(s)
- Sarah SJ Rewell
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - Amy L Jeffreys
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - Steven A Sastra
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - Susan F Cox
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - John A Fernandez
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - Elena Aleksoska
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - H Bart van der Worp
- Department of Neurology and Neurosurgery, Brain Center Rudolf Magus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Leonid Churilov
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - Malcolm R Macleod
- Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK
| | - David W Howells
- Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia
- School of Medicine, Faculty of Health, University of Tasmania, Hobart, Tasmania
- David W Howells, School of Medicine, Faculty of Health, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, Tasmania, Australia.
| |
Collapse
|
37
|
Zwetsloot PP, Van Der Naald M, Sena ES, Howells DW, IntHout J, De Groot JA, Chamuleau SA, MacLeod MR, Wever KE. Standardized mean differences cause funnel plot distortion in publication bias assessments. eLife 2017; 6:24260. [PMID: 28884685 PMCID: PMC5621838 DOI: 10.7554/elife.24260] [Citation(s) in RCA: 111] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Accepted: 08/21/2017] [Indexed: 01/07/2023] Open
Abstract
Meta-analyses are increasingly used for synthesis of evidence from biomedical research, and often include an assessment of publication bias based on visual or analytical detection of asymmetry in funnel plots. We studied the influence of different normalisation approaches, sample size and intervention effects on funnel plot asymmetry, using empirical datasets and illustrative simulations. We found that funnel plots of the Standardized Mean Difference (SMD) plotted against the standard error (SE) are susceptible to distortion, leading to overestimation of the existence and extent of publication bias. Distortion was more severe when the primary studies had a small sample size and when an intervention effect was present. We show that using the Normalised Mean Difference measure as effect size (when possible), or plotting the SMD against a sample size-based precision estimate, are more reliable alternatives. We conclude that funnel plots using the SMD in combination with the SE are unsuitable for publication bias assessments and can lead to false-positive results.
Collapse
Affiliation(s)
- Peter-Paul Zwetsloot
- Cardiology, Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht, Netherlands.,Netherlands Heart Institute, Utrecht, Netherlands
| | - Mira Van Der Naald
- Cardiology, Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht, Netherlands.,Netherlands Heart Institute, Utrecht, Netherlands
| | - Emily S Sena
- Center for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - David W Howells
- School of Medicine, University of Tasmania, Hobart, Australia
| | - Joanna IntHout
- Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands
| | - Joris Ah De Groot
- Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht, Netherlands
| | - Steven Aj Chamuleau
- Cardiology, Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht, Netherlands.,Netherlands Heart Institute, Utrecht, Netherlands.,Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, Netherlands
| | - Malcolm R MacLeod
- Center for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Kimberley E Wever
- Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands
| |
Collapse
|
38
|
Borschmann KN, Rewell SS, Iuliano S, Ghasem-Zadeh A, Davey RA, Ho H, Skeers PN, Bernhardt J, Howells DW. Reduced bone formation markers, and altered trabecular and cortical bone mineral densities of non-paretic femurs observed in rats with ischemic stroke: A randomized controlled pilot study. PLoS One 2017; 12:e0172889. [PMID: 28278253 PMCID: PMC5344372 DOI: 10.1371/journal.pone.0172889] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Accepted: 02/10/2017] [Indexed: 12/20/2022] Open
Abstract
Background Immobility and neural damage likely contribute to accelerated bone loss after stroke, and subsequent heightened fracture risk in humans. Objective To investigate the skeletal effect of middle cerebral artery occlusion (MCAo) stroke in rats and examine its utility as a model of human post-stroke bone loss. Methods Twenty 15-week old spontaneously hypertensive male rats were randomized to MCAo or sham surgery controls. Primary outcome: group differences in trabecular bone volume fraction (BV/TV) measured by Micro-CT (10.5 micron istropic voxel size) at the ultra-distal femur of stroke affected left legs at day 28. Neurological impairments (stroke behavior and foot-faults) and physical activity (cage monitoring) were assessed at baseline, and days 1 and 27. Serum bone turnover markers (formation: N-terminal propeptide of type 1 procollagen, PINP; resorption: C-terminal telopeptide of type 1 collagen, CTX) were assessed at baseline, and days 7 and 27. Results No effect of stroke was observed on BV/TV or physical activity, but PINP decreased by -24.5% (IQR -34.1, -10.5, p = 0.046) at day 27. In controls, cortical bone volume (5.2%, IQR 3.2, 6.9) and total volume (6.4%, IQR 1.2, 7.6) were higher in right legs compared to left legs, but these side-to-side differences were not evident in stroke animals. Conclusion MCAo may negatively affect bone formation. Further investigation of limb use and physical activity patterns after MCAo is required to determine the utility of this current model as a representation of human post-stroke bone loss.
Collapse
Affiliation(s)
- Karen N. Borschmann
- School of Allied Health, La Trobe University, Bundoora, Australia
- Stroke Division, The Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
- NHMRC Centre for Research Excellence in Stroke Rehabilitation and Recovery, Melbourne, Australia
- * E-mail:
| | - Sarah S. Rewell
- Stroke Division, The Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
| | - Sandra Iuliano
- Department of Endocrinology, Austin Health, University of Melbourne, Heidelberg, Australia
- Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia
| | - Ali Ghasem-Zadeh
- Department of Endocrinology, Austin Health, University of Melbourne, Heidelberg, Australia
- Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia
| | - Rachel A. Davey
- Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia
| | - Heidi Ho
- Stroke Division, The Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
| | - Peta N. Skeers
- Stroke Division, The Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
| | - Julie Bernhardt
- School of Allied Health, La Trobe University, Bundoora, Australia
- Stroke Division, The Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
- NHMRC Centre for Research Excellence in Stroke Rehabilitation and Recovery, Melbourne, Australia
| | - David W. Howells
- Stroke Division, The Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia
- University of Tasmania, School of Medicine, Faculty of Health, Hobart, Australia
| |
Collapse
|
39
|
Nguyen VA, Carey LM, Giummarra L, Faou P, Cooke I, Howells DW, Tse T, Macaulay SL, Ma H, Davis SM, Donnan GA, Crewther SG. A Pathway Proteomic Profile of Ischemic Stroke Survivors Reveals Innate Immune Dysfunction in Association with Mild Symptoms of Depression - A Pilot Study. Front Neurol 2016; 7:85. [PMID: 27379006 PMCID: PMC4907034 DOI: 10.3389/fneur.2016.00085] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Accepted: 05/23/2016] [Indexed: 12/14/2022] Open
Abstract
Depression after stroke is a common occurrence, raising questions as to whether depression could be a long-term biological and immunological sequela of stroke. Early explanations for post-stroke depression (PSD) focused on the neuropsychological/psychosocial effects of stroke on mobility and quality of life. However, recent investigations have revealed imbalances of inflammatory cytokine levels in association with PSD, though to date, there is only one published proteomic pathway analysis testing this hypothesis. Thus, we examined the serum proteome of stroke patients (n = 44, mean age = 63.62 years) and correlated these with the Montgomery–Åsberg Depression Rating Scale (MADRS) scores at 3 months post-stroke. Overall, the patients presented with mild depression symptoms on the MADRS, M = 6.40 (SD = 7.42). A discovery approach utilizing label-free relative quantification was employed utilizing an LC-ESI–MS/MS coupled to a LTQ-Orbitrap Elite (Thermo-Scientific). Identified peptides were analyzed using the gene set enrichment approach on several different genomic databases that all indicated significant downregulation of the complement and coagulation systems with increasing MADRS scores. Complement and coagulation systems are traditionally thought to play a key role in the innate immune system and are established precursors to the adaptive immune system through pro-inflammatory cytokine signaling. Both systems are known to be globally affected after ischemic or hemorrhagic stroke. Thus, our results suggest that lowered complement expression in the periphery in conjunction with depressive symptoms post-stroke may be a biomarker for incomplete recovery of brain metabolic needs, homeostasis, and inflammation following ischemic stroke damage. Further proteomic investigations are now required to construct the temporal profile, leading from acute lesion damage to manifestation of depressive symptoms. Overall, the findings provide support for the involvement of inflammatory and immune mechanisms in PSD symptoms and further demonstrate the value and feasibility of the proteomic approach in stroke research.
Collapse
Affiliation(s)
- Vinh A Nguyen
- Occupational Therapy, College of Science Health and Engineering, School of Allied Health, La Trobe University, Melbourne, VIC, Australia; Neurorehabilitation and Recovery, Stroke, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia; School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia
| | - Leeanne M Carey
- Occupational Therapy, College of Science Health and Engineering, School of Allied Health, La Trobe University, Melbourne, VIC, Australia; Neurorehabilitation and Recovery, Stroke, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
| | - Loretta Giummarra
- School of Psychology and Public Health, La Trobe University , Melbourne, VIC , Australia
| | - Pierre Faou
- School of Molecular Sciences, La Trobe University , Melbourne, VIC , Australia
| | - Ira Cooke
- School of Molecular Sciences, La Trobe University , Melbourne, VIC , Australia
| | - David W Howells
- School of Medicine, University of Tasmania , Hobart, TAS , Australia
| | - Tamara Tse
- Occupational Therapy, College of Science Health and Engineering, School of Allied Health, La Trobe University, Melbourne, VIC, Australia; Neurorehabilitation and Recovery, Stroke, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
| | - S Lance Macaulay
- Commonwealth Science and Industrial Research Organisation (CSIRO) , Melbourne, VIC , Australia
| | - Henry Ma
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia; Monash University, Clayton, VIC, Australia
| | - Stephen M Davis
- The University of Melbourne, Parkville, VIC, Australia; Department of Medicine, Melbourne Brain Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Geoffrey A Donnan
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia; The University of Melbourne, Parkville, VIC, Australia
| | - Sheila G Crewther
- Neurorehabilitation and Recovery, Stroke, The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia; School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia
| |
Collapse
|
40
|
Watzlawick R, Rind J, Sena ES, Brommer B, Zhang T, Kopp MA, Dirnagl U, Macleod MR, Howells DW, Schwab JM. Olfactory Ensheathing Cell Transplantation in Experimental Spinal Cord Injury: Effect size and Reporting Bias of 62 Experimental Treatments: A Systematic Review and Meta-Analysis. PLoS Biol 2016; 14:e1002468. [PMID: 27244556 PMCID: PMC4886956 DOI: 10.1371/journal.pbio.1002468] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 04/25/2016] [Indexed: 11/18/2022] Open
Abstract
Olfactory ensheathing cell (OEC) transplantation is a candidate cellular treatment approach for human spinal cord injury (SCI) due to their unique regenerative potential and autologous origin. The objective of this study was, through a meta-epidemiologic approach, (i) to assess the efficacy of OEC transplantation on locomotor recovery after traumatic experimental SCI and (ii) to estimate the likelihood of reporting bias and/or missing data. A study protocol was finalized before data collection. Embedded into a systematic review and meta-analysis, we conducted a literature research of databases including PubMed, EMBASE, and ISI Web of Science from 1949/01 to 2014/10 with no language restrictions, screened by two independent investigators. Studies were included if they assessed neurobehavioral improvement after traumatic experimental SCI, administrated no combined interventions, and reported the number of animals in the treatment and control group. Individual effect sizes were pooled using a random effects model. Details regarding the study design were extracted and impact of these on locomotor outcome was assessed by meta-regression. Missing data (reporting bias) was determined by Egger regression and Funnel-plotting. The primary study outcome assessed was improvement in locomotor function at the final time point of measurement. We included 49 studies (62 experiments, 1,164 animals) in the final analysis. The overall improvement in locomotor function after OEC transplantation, measured using the Basso, Beattie, and Bresnahan (BBB) score, was 20.3% (95% CI 17.8–29.5). One missing study was imputed by trim and fill analysis, suggesting only slight publication bias and reducing the overall effect to a 19.2% improvement of locomotor activity. Dose-response ratio supports neurobiological plausibility. Studies were assessed using a 9-point item quality score, resulting in a median score of 5 (interquartile range [IQR] 3–5). In conclusion, OEC transplantation exerts considerable beneficial effects on neurobehavioral recovery after traumatic experimental SCI. Publication bias was minimal and affirms the translational potential of efficacy, but safety cannot be adequately assessed. The data justify OECs as a cellular substrate to develop and optimize minimally invasive and safe cellular transplantation paradigms for the lesioned spinal cord embedded into state-of-the-art Phase I/II clinical trial design studies for human SCI. This meta-analysis study examines the effects of transplanting olfactory ensheathing cells in rodents with experimental spinal cord injury, finding evidence for significant recovery and identifying aspects of the procedure that influence the effect size. Spinal cord injury converts into a debilitating disease affecting millions of chronic patients worldwide. Despite increased molecular knowledge over the last decades, no causal pharmacological or cellular therapy has proven effective so far. Due to their unique regenerative capabilities and their autologous origin, olfactory ensheathing cells (OECs) constitute an appealing candidate for topical cell transplantation. In contrast to few and heterogeneous experimental reports of OEC transplantation after spinal cord injury in humans, a considerable number of preclinical studies have been conducted applying OEC transplantation in rodent models. We set out to conduct a systematic review and meta-analysis to assess preclinical efficacy of OEC transplantation. We detected a significant overall increase of functional neurological recovery in animals after OEC transplantation compared to the control group. This effect was not distorted by publication bias. We identified several specific hallmarks of the cell transplantation procedure that determine the effect size of the transplantation. Our findings delineate conditions for optimized OEC transplantation into lesioned spinal cords and its relevance for effective translation to human trials.
Collapse
Affiliation(s)
- Ralf Watzlawick
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité–Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurosurgery, University Medical Center Freiburg, Freiburg, Germany
| | - Julian Rind
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité–Universitätsmedizin Berlin, Berlin, Germany
| | - Emily S. Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
| | - Benedikt Brommer
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité–Universitätsmedizin Berlin, Berlin, Germany
- F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, Boston, United States of America
| | - Tian Zhang
- Center for Stroke Research Berlin, Charité–Universitätsmedizin, Berlin, Germany
| | - Marcel A. Kopp
- Center for Stroke Research Berlin, Charité–Universitätsmedizin, Berlin, Germany
| | - Ulrich Dirnagl
- Center for Stroke Research Berlin, Charité–Universitätsmedizin, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE) Berlin site, Berlin, Germany
| | - Malcolm R. Macleod
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - David W. Howells
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
- University of Tasmania, School of Medicine, Faculty of Health, Medical Sciences Precinct, Hobart, Tasmania, Australia
| | - Jan M. Schwab
- Department of Neurology and Experimental Neurology, Charité Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charité–Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology, Spinal Cord Injury Division, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus, United States of America
- Department of Neuroscience and Center for Brain and Spinal Cord Repair, Department of Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Center, Columbus, United States of America
- * E-mail:
| |
Collapse
|
41
|
Yang X, Zhang X, Li Y, Han S, Howells DW, Li S, Li J. Conventional protein kinase Cβ-mediated phosphorylation inhibits collapsin response-mediated protein 2 proteolysis and alleviates ischemic injury in cultured cortical neurons and ischemic stroke-induced mice. J Neurochem 2016; 137:446-59. [PMID: 26788931 DOI: 10.1111/jnc.13538] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Revised: 01/07/2016] [Accepted: 01/11/2016] [Indexed: 01/13/2023]
Abstract
We previously reported that conventional protein kinase C (cPKC)β participated in hypoxic preconditioning-induced neuroprotection against cerebral ischemic injury, and collapsin response-mediated protein 2 (CRMP2) was identified as a cPKCβ interacting protein. In this study, we explored the regulation of CRMP2 phosphorylation and proteolysis by cPKCβ, and their role in ischemic injury of oxygen-glucose deprivation (OGD)-treated cortical neurons and brains of mice with middle cerebral artery occlusion-induced ischemic stroke. The results demonstrated that cPKCβ-mediated CRMP2 phosphorylation via the cPKCβ-selective activator 12-deoxyphorbol 13-phenylacetate 20-acetate (DOPPA) and inhibition of calpain-mediated CRMP2 proteolysis by calpeptin and a fusing peptide containing TAT peptide and the calpain cleavage site of CRMP2 (TAT-CRMP2) protected neurons against OGD-induced cell death through inhibiting CRMP2 proteolysis in cultured cortical neurons. The OGD-induced nuclear translocation of the CRMP2 breakdown product was inhibited by DOPPA, calpeptin, and TAT-CRMP2 in cortical neurons. In addition, both cPKCβ activation and CRMP2 proteolysis inhibition by hypoxic preconditioning and intracerebroventricular injections of DOPPA, calpeptin, and TAT-CRMP2 improved the neurological deficit in addition to reducing the infarct volume and proportions of cells with pyknotic nuclei in the peri-infact region of mice with ischemic stroke. These results suggested that cPKCβ modulates CRMP2 phosphorylation and proteolysis, and cPKCβ activation alleviates ischemic injury in the cultured cortical neurons and brains of mice with ischemic stroke through inhibiting CRMP2 proteolysis by phosphorylation. Focal cerebral ischemia induces a large flux of Ca(2+) to activate calpain which cleaves collapsin response mediator (CRMP) 2 into breakdown product (BDP). Inhibition of CRMP2 cleavage by calpeptin and TAT-CRMP2 alleviates ischemic injury. Conventional protein kinase C (cPKC)β-mediated phosphorylation could inhibit CRMP2 proteolysis and alleviate ischemic injury in cultured cortical neurons and ischemic stroke-induced mice.
Collapse
Affiliation(s)
- Xuan Yang
- Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - Xinxin Zhang
- Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - Yun Li
- Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - Song Han
- Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - David W Howells
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
| | - Shujuan Li
- Department of Neurology, Capital Medical University Affiliated Beijing Chao-Yang Hospital, Beijing, China
| | - Junfa Li
- Department of Neurobiology and Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| |
Collapse
|
42
|
Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, Antonic A, Howells DW, Macleod MR. Corrigendum to 'Meta-analysis of data from animal studies: A practical guide': [Journal of Neuroscience Methods 221 (2014) 92-102]. J Neurosci Methods 2016; 259:156. [PMID: 28760532 DOI: 10.1016/j.jneumeth.2015.11.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- H M Vesterinen
- Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, United Kingdom
| | - E S Sena
- Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, United Kingdom; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - K J Egan
- Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, United Kingdom
| | - T C Hirst
- Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, United Kingdom
| | - L Churolov
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - G L Currie
- Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, United Kingdom
| | - A Antonic
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - D W Howells
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - M R Macleod
- Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, United Kingdom.
| |
Collapse
|
43
|
Affiliation(s)
- Ralf Watzlawick
- Department of Neurology and Experimental Neurology, Spinal Cord Injury Research, Charité–Universitätsmedizin Berlin, Berlin, Germany
| | - David W. Howells
- Faculty of Heath, School of Medicine, University of Tasmania, Medical Sciences Precinct, Hobart, Tasmania, Australia
| | - Jan M. Schwab
- Spinal Cord Injury Division, Department of Neurology, The Ohio State University, Wexner Medical Center, Columbus4Department of Neuroscience and Center for Brain and Spinal Cord Repair, The Ohio State University, Wexner Medical Center, Columbus
| |
Collapse
|
44
|
Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, Hirst T, Hemblade R, Bahor Z, Nunes-Fonseca C, Potluru A, Thomson A, Baginskaite J, Egan K, Vesterinen H, Currie GL, Churilov L, Howells DW, Sena ES. Correction: Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biol 2015; 13:e1002301. [PMID: 26556632 PMCID: PMC4640855 DOI: 10.1371/journal.pbio.1002301] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
45
|
Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, Hirst T, Hemblade R, Bahor Z, Nunes-Fonseca C, Potluru A, Thomson A, Baginskitae J, Egan K, Vesterinen H, Currie GL, Churilov L, Howells DW, Sena ES. Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biol 2015; 13:e1002273. [PMID: 26460723 PMCID: PMC4603955 DOI: 10.1371/journal.pbio.1002273] [Citation(s) in RCA: 189] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The reliability of experimental findings depends on the rigour of experimental design. Here we show limited reporting of measures to reduce the risk of bias in a random sample of life sciences publications, significantly lower reporting of randomisation in work published in journals of high impact, and very limited reporting of measures to reduce the risk of bias in publications from leading United Kingdom institutions. Ascertainment of differences between institutions might serve both as a measure of research quality and as a tool for institutional efforts to improve research quality.
Collapse
Affiliation(s)
- Malcolm R. Macleod
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Aaron Lawson McLean
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | | | - Stylianos Serghiou
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Arno de Wilde
- Medical School, University Medical Centre, Utrecht, Netherlands
| | - Nicki Sherratt
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Theo Hirst
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Rachel Hemblade
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Zsanett Bahor
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | | | - Aparna Potluru
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Andrew Thomson
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Julija Baginskitae
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Kieren Egan
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Hanna Vesterinen
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Gillian L. Currie
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Leonid Churilov
- Statistics and Informatics Platform, Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
| | | | - Emily S. Sena
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Statistics and Informatics Platform, Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
| |
Collapse
|
46
|
Kleikers PWM, Hooijmans C, Göb E, Langhauser F, Rewell SSJ, Radermacher K, Ritskes-Hoitinga M, Howells DW, Kleinschnitz C, HHW Schmidt H. A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. Sci Rep 2015; 5:13428. [PMID: 26310318 PMCID: PMC4550831 DOI: 10.1038/srep13428] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 07/27/2015] [Indexed: 12/30/2022] Open
Abstract
Biomedical research suffers from a dramatically poor translational success. For example, in ischemic stroke, a condition with a high medical need, over a thousand experimental drug targets were unsuccessful. Here, we adopt methods from clinical research for a late-stage pre-clinical meta-analysis (MA) and randomized confirmatory trial (pRCT) approach. A profound body of literature suggests NOX2 to be a major therapeutic target in stroke. Systematic review and MA of all available NOX2(-/y) studies revealed a positive publication bias and lack of statistical power to detect a relevant reduction in infarct size. A fully powered multi-center pRCT rejects NOX2 as a target to improve neurofunctional outcomes or achieve a translationally relevant infarct size reduction. Thus stringent statistical thresholds, reporting negative data and a MA-pRCT approach can ensure biomedical data validity and overcome risks of bias.
Collapse
Affiliation(s)
- Pamela WM. Kleikers
- Department of Pharmacology, CARIM, Faculty of Health, Medicine and Life Sciences, Maastricht University, The Netherlands
| | - Carlijn Hooijmans
- SYRCLE at Central Animal Laboratory, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - Eva Göb
- Neurologische Klinik und Poliklinik der Universitätsklinik Würzburg, Würzburg, Germany
| | - Friederike Langhauser
- Neurologische Klinik und Poliklinik der Universitätsklinik Würzburg, Würzburg, Germany
| | - Sarah SJ. Rewell
- Florey Institute of Neuroscience and Mental Health, Austin Health, Melbourne, Victoria, Australia
| | - Kim Radermacher
- Department of Pharmacology, CARIM, Faculty of Health, Medicine and Life Sciences, Maastricht University, The Netherlands
| | - Merel Ritskes-Hoitinga
- SYRCLE at Central Animal Laboratory, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - David W. Howells
- Florey Institute of Neuroscience and Mental Health, Austin Health, Melbourne, Victoria, Australia
| | | | - Harald HHW Schmidt
- Department of Pharmacology, CARIM, Faculty of Health, Medicine and Life Sciences, Maastricht University, The Netherlands
| |
Collapse
|
47
|
Pascoe MC, Howells DW, Crewther DP, Carey LM, Crewther SG. Fish oil supplementation associated with decreased cellular degeneration and increased cellular proliferation 6 weeks after middle cerebral artery occlusion in the rat. Neuropsychiatr Dis Treat 2015; 11:153-64. [PMID: 25609971 PMCID: PMC4298295 DOI: 10.2147/ndt.s72925] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Anti-inflammatory long-chain omega-3 polyunsaturated fatty acids (n-3-LC-PUFAs) are both neuroprotective and have antidepressive effects. However the influence of dietary supplemented n-3-LC-PUFAs on inflammation-related cell death and proliferation after middle cerebral artery occlusion (MCAo)-induced stroke is unknown. We have previously demonstrated that anxiety-like and hyperactive locomotor behaviors are reduced in n-3-LC-PUFA-fed MCAo animals. Thus in the present study, male hooded Wistar rats were exposed to MCAo or sham surgeries and examined behaviorally 6 weeks later, prior to euthanasia and examination of lesion size, cell death and proliferation in the dentate gyrus, cornu ammonis region of the hippocampus of the ipsilesional hemispheres, and the thalamus of the ipsilesional and contralesional hemispheres. Markers of cell genesis and cell degeneration in the hippocampus or thalamus of the ipsilesional hemisphere did not differ between surgery and diet groups 6 weeks post MCAo. Dietary supplementation with n-3-LC-PUFA decreased cell degeneration and increased cell proliferation in the thalamic region of the contralesional hemisphere. MCAo-associated cell degeneration in the hippocampus and thalamus positively correlated with anxiety-like and hyperactive locomotor behaviors previously reported in these animals. These results suggest that anti-inflammatory n-3-LC-PUFA supplementation appears to have cellular protective effects after MCAo in the rat, which may affect behavioral outcomes.
Collapse
Affiliation(s)
| | - David W Howells
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC, Australia
| | | | - Leeanne M Carey
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC, Australia ; Department of Occupational Therapy, School of Allied Health La Trobe University, VIC, Australia
| | - Sheila G Crewther
- School of Psychological Science, La Trobe University, Melbourne, VIC, Australia
| |
Collapse
|
48
|
McCann SK, Irvine C, Mead GE, Sena ES, Currie GL, Egan KE, Macleod MR, Howells DW. Efficacy of antidepressants in animal models of ischemic stroke: a systematic review and meta-analysis. Stroke 2014; 45:3055-63. [PMID: 25184357 DOI: 10.1161/strokeaha.114.006304] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND AND PURPOSE Poststroke depression is a prevalent complication of stroke with unclear pathogenesis. The benefits of antidepressants in this context and their effects on stroke recovery other than effects on mood are not clearly defined, with some studies suggesting efficacy in improving functional outcome in both depressed and nondepressed stroke patients. We have analyzed the preclinical animal data on antidepressant treatment in focal cerebral ischemia, modeled±depression, to help inform clinical trial design. METHODS We performed a systematic review and meta-analysis of data from experiments testing the efficacy of antidepressants versus no treatment to reduce infarct volume or improve neurobehavioral or neurogenesis outcomes in animal models of stroke. We used random-effects metaregression to test the impact of study quality and design characteristics and used trim and fill to assess publication bias. RESULTS We identified 44 publications describing the effects of 22 antidepressant drugs. The median quality checklist score was 5 of a possible 10 (interquartile range, 4-7). Overall, antidepressants reduced infarct volume by 27.3% (95% confidence interval, 20.7%-33.8%) and improved neurobehavioral outcomes by 53.7% (46.4%-61.1%). There was little evidence for an effect of selective serotonin reuptake inhibitors on infarct volume. For neurobehavioral outcomes there was evidence of publication bias. Selective serotonin reuptake inhibitors were the most frequently studied antidepressant subtype and improved neurobehavioral outcome by 51.8% (38.6%-64.9%) and increased neurogenesis by 2.2 SD (1.3-3.0). CONCLUSIONS In line with current clinical data and despite some limitations, antidepressant treatments seem to improve infarct volume and neurobehavioral outcome in animal models of ischemic stroke.
Collapse
Affiliation(s)
- Sarah K McCann
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M)
| | - Cadi Irvine
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M)
| | - Gillian E Mead
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M)
| | - Emily S Sena
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M)
| | - Gillian L Currie
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M)
| | - Kieren E Egan
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M)
| | - Malcolm R Macleod
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M).
| | - David W Howells
- From The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia (S.K.M., E.S.S., D.W.H.); and Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom (C.I., G.E.M., E.S.S., G.L.C., K.E.E., M.R.M)
| |
Collapse
|
49
|
Antonic A, Dottori M, Leung J, Sidon K, Batchelor PE, Wilson W, Macleod MR, Howells DW. Hypothermia protects human neurons. Int J Stroke 2014; 9:544-52. [PMID: 24393199 PMCID: PMC4235397 DOI: 10.1111/ijs.12224] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2013] [Accepted: 10/14/2013] [Indexed: 12/23/2022]
Abstract
BACKGROUND AND AIMS Hypothermia provides neuroprotection after cardiac arrest, hypoxic-ischemic encephalopathy, and in animal models of ischemic stroke. However, as drug development for stroke has been beset by translational failure, we sought additional evidence that hypothermia protects human neurons against ischemic injury. METHODS Human embryonic stem cells were cultured and differentiated to provide a source of neurons expressing β III tubulin, microtubule-associated protein 2, and the Neuronal Nuclei antigen. Oxygen deprivation, oxygen-glucose deprivation, and H2 O2 -induced oxidative stress were used to induce relevant injury. RESULTS Hypothermia to 33°C protected these human neurons against H2 O2 -induced oxidative stress reducing lactate dehydrogenase release and Terminal deoxynucleotidyl transferase dUTP nick end labeling-staining by 53% (P ≤ 0·0001; 95% confidence interval 34·8-71·04) and 42% (P ≤ 0·0001; 95% confidence interval 27·5-56·6), respectively, after 24 h in culture. Hypothermia provided similar protection against oxygen-glucose deprivation (42%, P ≤ 0·001, 95% confidence interval 18·3-71·3 and 26%, P ≤ 0·001; 95% confidence interval 12·4-52·2, respectively) but provided no protection against oxygen deprivation alone. Protection (21%) persisted against H2 O2 -induced oxidative stress even when hypothermia was initiated six-hours after onset of injury (P ≤ 0·05; 95% confidence interval 0·57-43·1). CONCLUSION We conclude that hypothermia protects stem cell-derived human neurons against insults relevant to stroke over a clinically relevant time frame. Protection against H2 O2 -induced injury and combined oxygen and glucose deprivation but not against oxygen deprivation alone suggests an interaction in which protection benefits from reduction in available glucose under some but not all circumstances.
Collapse
Affiliation(s)
- Ana Antonic
- Florey Institute of Neuroscience and Mental HealthHeidelberg, Vic, Australia
- Department of Medicine, University of MelbourneHeidelberg, Vic, Australia
| | - Mirella Dottori
- Centre for Neuroscience Research, Department of Anatomy and Neuroscience, University of MelbourneMelbourne, Vic, Australia
| | - Jessie Leung
- Centre for Neuroscience Research, Department of Anatomy and Neuroscience, University of MelbourneMelbourne, Vic, Australia
| | - Kate Sidon
- Florey Institute of Neuroscience and Mental HealthHeidelberg, Vic, Australia
- Department of Medicine, University of MelbourneHeidelberg, Vic, Australia
| | - Peter E Batchelor
- Department of Medicine, University of MelbourneHeidelberg, Vic, Australia
| | - William Wilson
- CSIRO Mathematics, Informatics and Statistics, Riverside Life Sciences PrecinctNorth Ryde, NSW, Australia
| | - Malcolm R Macleod
- Department of Clinical Neurosciences, Western General Hospital, University of EdinburghEdinburgh, UK
| | - David W Howells
- Florey Institute of Neuroscience and Mental HealthHeidelberg, Vic, Australia
- Department of Medicine, University of MelbourneHeidelberg, Vic, Australia
| |
Collapse
|
50
|
Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW. Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab 2014; 34:737-42. [PMID: 24549183 PMCID: PMC4013765 DOI: 10.1038/jcbfm.2014.28] [Citation(s) in RCA: 168] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 01/21/2014] [Indexed: 01/31/2023]
Abstract
The use of systematic review and meta-analysis of preclinical studies has become more common, including those of studies describing the modeling of cerebrovascular diseases. Empirical evidence suggests that too many preclinical experiments lack methodological rigor, and this leads to inflated treatment effects. The aim of this review is to describe the concepts of systematic review and meta-analysis and consider how these tools may be used to provide empirical evidence to spur the field to improve the rigor of the conduct and reporting of preclinical research akin to their use in improving the conduct and reporting of randomized controlled trials in clinical research. As with other research domains, systematic reviews are subject to bias. Therefore, we have also suggested guidance for their conduct, reporting, and critical appraisal.
Collapse
Affiliation(s)
- Emily S Sena
- Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
| | - Gillian L Currie
- Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK
| | - Sarah K McCann
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
| | - Malcolm R Macleod
- Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK
| | - David W Howells
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
| |
Collapse
|